0001662252-17-000160.txt : 20170810 0001662252-17-000160.hdr.sgml : 20170810 20170810125304 ACCESSION NUMBER: 0001662252-17-000160 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 45 CONFORMED PERIOD OF REPORT: 20170630 FILED AS OF DATE: 20170810 DATE AS OF CHANGE: 20170810 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Regenicin, Inc. CENTRAL INDEX KEY: 0001412659 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 000000000 STATE OF INCORPORATION: NV FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 333-146834 FILM NUMBER: 171020672 BUSINESS ADDRESS: STREET 1: 10 HIGH COURT CITY: LITTLE FALLS STATE: NJ ZIP: 07424 BUSINESS PHONE: (973) 557-8914 MAIL ADDRESS: STREET 1: 10 HIGH COURT CITY: LITTLE FALLS STATE: NJ ZIP: 07424 FORMER COMPANY: FORMER CONFORMED NAME: Windstar Inc. DATE OF NAME CHANGE: 20070918 10-Q 1 rgin10q.htm 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 10-Q

 

[X] Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
   
  For the quarterly period ended June 30, 2017
   
[  ] Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934
   
  For the transition period from                  to __________
   
  Commission File Number: 333-146834  

 

Regenicin, Inc.
(Exact name of registrant as specified in its charter)

 

Nevada 27-3083341
(State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.)

 

10 High Court, Little Falls, NJ
(Address of principal executive offices)

 

(973) 557-8914
(Registrant’s telephone number)
 
_______________________________________________________________
(Former name, former address and former fiscal year, if changed since last report)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days [ ] Yes [X] No

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). [ ] Yes [X] No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.

 

[ ] Large accelerated filer

[ ] Non-accelerated filer

[ ] Accelerated filer

[X] Smaller reporting company

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). [ ] Yes [X] No

 

State the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 153,483,050 as of August 1, 2016.

 1 

 

  TABLE OF CONTENTS Page 
 
PART I – FINANCIAL INFORMATION
 
Item 1: Financial Statements 3
Item 2: Management’s Discussion and Analysis of Financial Condition and Results of Operations 4
Item 3: Quantitative and Qualitative Disclosures About Market Risk 7
Item 4: Controls and Procedures 7
PART II – OTHER INFORMATION
Item 1: Legal Proceedings 8
Item 1A: Risk Factors 8
Item 2: Unregistered Sales of Equity Securities and Use of Proceeds 8
Item 3: Defaults Upon Senior Securities 8
Item 4: Mine Safety Disclosures 8
Item 5: Other Information
8
Item 6: Exhibits
8

 

 2 

 

PART I - FINANCIAL INFORMATION

 

Item 1. Financial Statements

 

Our consolidated financial statements included in this Form 10-Q are as follows:

 

F-1 Consolidated Balance Sheets as of June 30, 2017 (unaudited) and September 30, 2016;
F-2 Consolidated Statements of Operations for the three and nine months ended June 30, 2017 and 2016 (unaudited);
F-3 Consolidated Statements of Comprehensive Loss for the three and nine months ended June 30, 2017 and 2016 (unaudited);
F-4 Consolidated Statements of Cash Flows for the nine months ended June 30, 2017 and 2016 (unaudited); and
F-5 Notes to Consolidated Financial Statements.

 

These consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and the SEC instructions to Form 10-Q. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. Operating results for the interim period ended June 30, 2017 are not necessarily indicative of the results that can be expected for the full year.

 

 3 

REGENICIN, INC. AND SUBSIDIARY

CONSOLIDATED BALANCE SHEETS 

 

  June 30,  September 30,
  2017  2016
   (UNAUDITED)      
ASSETS         
CURRENT ASSETS         
Cash $12,005   $218,847 
Prepaid expenses and other current assets  25,986    66,218 
Due from related party  10,000    —   
Common stock of Amarantus Corporation  9,075    7,500 
Total current assets  57,066    292,565 
Due from related party  —      67,268 
Total assets $57,066   $359,833 
          
LIABILITIES AND STOCKHOLDERS' DEFICIENCY         
CURRENT LIABILITIES         
Accounts payable $270,423   $262,934 
Accrued expenses - other  275,316    230,897 
Accrued salaries - officers  1,571,751    1,136,001 
Bridge financing  175,000    175,000 
Loan payable  10,000    10,000 
Loans payable - officer  —      13,009 
Total current and total liabilities  2,302,490    1,827,841 
          
STOCKHOLDERS' DEFICIENCY         
Series A 10% Convertible Preferred stock, $0.001 par value,5,500,000 shares authorized; 885,000 issued and outstanding  885    885 
Common stock, $0.001 par value; 200,000,000 shares authorized; 157,911,410 issued and 153,483,050 outstanding  157,914    157,914 
Additional paid-in capital  10,177,515    10,177,515 
Accumulated deficit  (12,578,885)   (11,799,894)
Accumulated other comprehensive income  1,575    —   
Less: treasury stock; 4,428,360 shares at par  (4,428)   (4,428)
Total stockholders' deficiency  (2,245,424)   (1,468,008)
Total liabilities and stockholders' deficiency $57,066   $359,833 

 

See Notes to Consolidated Financial Statements.

 F-1 

REGENICIN, INC. AND SUBSIDIARY

CONSOLIDATED STATEMENTS OF OPERATIONS

 

  Nine Months  Nine Months  Three Months  Three Months
  Ended  Ended  Ended  Ended
  June 30,  June 30,  June 30,  June 30,
  2017  2016  2017  2016
  (UNAUDITED)  (UNAUDITED)  (UNAUDITED)  (UNAUDITED)
            
Revenues $—     $—     $—     $—   
                    
Operating expenses                   
Research and development  5,284    1,445    —      —   
General and administrative  780,288    885,058    194,966    305,470 
Stock based compensation - general and administrative  —      67,895    —      —   
Total operating expenses  785,572    954,398    194,966    305,470 
                    
Operating loss before other operating income  (785,572)   (954,398)   (194,966)   (305,470)
Other operating income - reversal of accounts payable  15,000    —      —      —   
Loss from operations  (770,572)   (954,398)   (194,966)   (305,470)
                    
Other income (expenses)                   
Interest expense  (13,089)   (13,137)   (4,363)   (4,363)
Interest income  4,670    —      495    —   
Total other income (expenses)  (8,419)   (13,137)   (3,868)   (4,363)
Net loss  (778,991)   (967,535)   (198,834)   (309,833)
Preferred stock dividends  (52,955)   (53,149)   (17,652)   (17,652)
Net loss available to common stockholders $(831,946)  $(1,020,684)  $(216,486)  $(327,485)
                    
Loss per share:                   
   Basic $(0.01)  $(0.01)  $(0.00)  $(0.00)
   Diluted $(0.01)  $(0.01)  $(0.00)  $(0.00)
                    
Weighted average number of shares outstanding                   
   Basic  153,483,050    153,483,050    153,483,050    153,483,050 
   Diluted  153,483,050    153,483,050    153,483,050    153,483,050 

 

See Notes to Consolidated Financial Statements.

 F-2 

REGENICIN, INC. AND SUBSIDIARY

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

 

  Nine Months  Nine Months  Three Months  Three Months
  Ended  Ended  Ended  Ended
  June 30,  June 30,  June 30,  June 30,
  2017  2016  2017  2016
  (UNAUDITED)  (UNAUDITED)  (UNAUDITED)  (UNAUDITED)
            
Net loss $(778,991)  $(967,535)  $(198,834)  $(309,833)
                    
Other comprehensive income (loss):                   
                    
Change in unrealized gain (loss) on available-for-sale securities, net of income taxes  1,575    (287,250)   (6,400)   (900)
                    
Comprehensive loss $(777,416)  $(1,254,785)  $(205,234)  $(310,733)

 

See Notes to Consolidated Financial Statements.

 F-3 

REGENICIN, INC. AND SUBSIDIARY

CONSOLIDATED STATEMENTS OF CASH FLOWS

 

  Nine Months  Nine Months
  Ended  Ended
  June 30,  June 30,
  2017  2016
  (UNAUDITED)  (UNAUDITED)
      
CASH FLOWS FROM OPERATING ACTIVITIES         
     Net loss $(778,991)  $(967,535)
     Adjustments to reconcile net income to net cash used in operating activities:         
         Accrued interest on notes and loans payable  13,089    13,137 
         Stock based compensation - general and administrative  —      67,895 
         Reversal of accounts payable  (15,000)   —   
         Changes in operating assets and liabilities         
              Prepaid expenses and other current assets  40,232    71,807 
              Accounts payable  22,489    (21,580)
              Accrued expenses  31,330    51,652 
              Accrued salaries - officers  435,750    189,000 
Net cash used in operating activities  (251,101)   (595,624)
          
CASH FLOWS FROM INVESTING ACTIVITIES         
         Proceeds from repayment of loans from related party  67,268    —   
         Advances to related parties  (10,000)   (64,622)
Net cash provided by (used in) investing activities  57,268    (64,622)
          
CASH FLOWS FROM FINANCING ACTIVITIES         
         Proceeds of loans from officers  —      15,500 
         Repayment of loans from officers  (13,009)   (73,203)
Net cash used in financing activities  (13,009)   (57,703)
          
NET DECREASE IN CASH  (206,842)   (717,949)
CASH - BEGINNING OF PERIOD  218,847    1,061,377 
CASH - END OF PERIOD $12,005   $343,428 
          
Supplemental disclosures of cash flow information:         
       Cash paid for interest $—     $—   
       Cash paid for taxes $—     $—   

 

See Notes to Consolidated Financial Statements. 

 F-4 

REGENICIN, INC. AND SUBSIDIARY

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

 

NOTE 1 - THE COMPANY  

 

Windstar, Inc. was incorporated in the state of Nevada on September 6, 2007. On July 19, 2010, the Company amended its Articles of Incorporation to change the name of the Company to Regenicin, Inc. (“Regenicin”). In September 2013, Regenicin formed a new wholly-owned subsidiary for the sole purpose of conducting research in the State of Georgia (together, the “Company”). The subsidiary has no activity since its formation due to the lack of funding. The Company’s original business was the development of a purification device. Such business was assigned to the Company’s former management in July 2010. The Company adopted a new business plan and intended to develop and commercialize a potentially lifesaving technology by the introduction of tissue-engineered skin substitutes to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds and a variety of plastic surgery procedures.

 

The Company entered into a Know-How License and Stock Purchase Agreement (the “Know-How SPA”) with Lonza Walkersville, Inc. (“Lonza Walkersville”) on July 21, 2010. Pursuant to the terms of the Know-How SPA, the Company paid Lonza Walkersville $3,000,000 and, in exchange, the Company was to receive an exclusive license to use certain proprietary know-how and information necessary to develop and seek approval by the U.S. Food and Drug Administration (“FDA”) for the commercial sale of technology held by the Cutanogen Corporation (“Cutanogen”), a subsidiary of Lonza Walkersville. Additionally, pursuant to the terms of the Know-How SPA, the Company was entitled to receive certain related assistance and support from Lonza Walkersville upon payment of the $3,000,000. Under the Know-How SPA, once FDA approval was secured for the commercial sale of the technology, the Company would be entitled to acquire Cutanogen, Lonza Walkersville’s subsidiary, for $2,000,000 in cash. After prolonged attempts to negotiate disputes with Lonza Walkersville failed, on September 30, 2013, the Company filed a lawsuit against Lonza Walkersville, Lonza Group Ltd. and Lonza America, Inc. (“Lonza America”) in Fulton County Superior Court in the State of Georgia.

 

On November 7, 2014, the Company entered into an Asset Sale Agreement (the “Sale Agreement”) with Amarantus Bioscience Holdings, Inc., (“Amarantus”). Under the Sale Agreement, the Company agreed to sell to Amarantus all of its rights and claims in the litigation currently pending in the United States District Court for the District of New Jersey against Lonza Walkersville and Lonza America, Inc. (the “Lonza Litigation”). This includes all of the Cutanogen intellectual property rights and any Lonza manufacturing know-how technology. In addition, the Company agreed to sell the PermaDerm® trademark and related intellectual property rights associated with it. The purchase price paid by Amarantus was: (i) $3,600,000 in cash, and (ii) shares of common stock in Amarantus having a value of $3,000,000 at the date of the transaction.

 

The Company used the net proceeds of the transaction to fund development of cultured cell technology and to pursue approval of the products through the FDA as well as for general and administrative expenses. The Company has been developing its own unique cultured skin substitute since the Company received Lonza’s termination notice.

 

NOTE 2 - BASIS OF PRESENTATION

 

Interim Financial Statements:

 

The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and note disclosures required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the nine months ended June 30, 2017 are not necessarily indicative of the results that may be expected for the year ending September 30, 2017. These unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and footnotes thereto included in the Company's Annual Report on Form 10-K for the year ended September 30, 2016, as filed with the Securities and Exchange Commission.

 

 F-5 

 

Going Concern:

 

The Company's consolidated financial statements have been prepared assuming that the Company will continue as a going concern which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has incurred cumulative losses and has an accumulated deficit of approximately $12.6 million from inception, expects to incur further losses in the development of its business and has been dependent on funding operations through the issuance of convertible debt, private sale of equity securities, and the proceeds from the Sale Agreement. These conditions raise substantial doubt about the Company's ability to continue as a going concern. The Company is using the proceeds from the Sale Agreement to fund operations. Once the funds are exhausted, management plans to finance operations through the private or public placement of debt and/or equity securities. However, no assurance can be given at this time as to whether the Company will be able to obtain such financing. The consolidated financial statements do not include any adjustment relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

 

Financial Instruments and Fair Value Measurement:

 

The Company measures fair value of its financial assets on a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:

 

• Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.

 

• Level 2 - Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable or inputs that can be corroborated by observable market data for substantially the full term of the assets or liabilities.

 

• Level 3 - Unobservable inputs which are supported by little or no market activity.

 

The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.

 

The carrying value of cash, prepaid expenses and other current assets, accounts payable, accrued expenses and all loans and notes payable in the Company’s consolidated balance sheets approximated their fair values as of June 30, 2017 and September 30, 2016 due to their short-term nature.

 

Common stock of Amarantus represents equity investments in common stock that the Company classifies as available for sale. Such investments are carried at fair value in the accompanying consolidated balance sheets. Fair value is determined under the guidelines of GAAP which defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. Realized gains and losses, determined using the first-in, first-out (FIFO) method, are included in net income (loss). Unrealized gains and losses considered to be temporary are reported as other comprehensive income (loss) and are included in stockholders equity. Other than temporary declines in the fair value of investment is included in other income (expense) on the statement of operations.

 

The common stock of Amarantus is valued at the closing price reported on the active market on which the security is traded. This valuation methodology is considered to be using Level 1 inputs. The total value of Amarantus common stock at June 30, 2017 is $9,075. The unrealized gain (loss) for the nine and three months ended June 30, 2017 was $1,575 and ($6,400), net of income taxes, respectively, and was reported as a component of comprehensive loss. The unrealized loss for the the nine and three months ended June 30, 2016 was ($287,250) and $(900), net of income taxes, respectively, and was also reported as a component of comprehensive loss. The Company has recognized other than temporary losses of $2,992,500 since the acquisition of the stock in connection with the Sale Agreement.

 

 F-6 

 

Reclassification:

 

Certain reclassifications have been made to the prior periods’ statement of cash flows to conform to the current period’s presentation. The reclassifications did not affect the net income or retained earnings of the Company.

 

Recent Pronouncements:

 

In January 2016, the FASB issued ASU No. 2016-01, "Financial Instruments-Overall: Recognition and Measurement of Financial Assets and Financial Liabilities". The new standard principally affects accounting standards for equity investments and financial liabilities where the fair value option has been elected, and the presentation and disclosure requirements for financial instruments. Upon the effective date of the new standards, all equity investments in unconsolidated entities, other than those accounted for using the equity method of accounting, will generally be measured at fair value through earnings. There will no longer be an available-for-sale classification and therefore, no changes in fair value will be reported in other comprehensive income (loss) for equity securities with readily determinable fair values. The new guidance on the classification and measurement will be effective for public business entities in fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The Company is currently evaluating the impact of ASU 2016-01 on its consolidated financial statements. 

 

In February 2016, the FASB issued ASU 2016-02, Leases, (Topic 842). This new ASU represents a wholesale change to lease accounting and introduces a lease model that brings most leases on the balance sheet. It also eliminates the required use of bright-line tests in current U.S. GAAP for determining lease classification. This ASU is effective for annual periods beginning after December 15, 2018 (i.e., calendar periods beginning on January 1, 2019), and interim periods thereafter. Earlier application is permitted for all entities. The Company is currently evaluating the impact of ASU 2016-02 on its consolidated financial statements.

 

In March 2016, the FASB issued ASU No. 2016-09, Improvements to Employee Share-Based Payment Accounting, which is intended to simplify the accounting and reporting for employee share-based payment transactions. The pronouncement is effective for annual periods beginning after December 31, 2016, and with interim periods within those annual periods, with early adoption permitted. The adoption of this guidance is not expected to have a material impact on the Company's consolidated financial statements.

 

In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation, which is intended to reduce both (1) diversity in practice and (2) cost and complexity when applying the guidance in Topic 718, Compensation—Stock Compensation, to a change to the terms or conditions of a share-based payment award. The amendments in this Update are effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017 with early adoption permitted. The adoption of this guidance did not have a material impact on the Company's consolidated financial statements.

 

All other recent pronouncements issued by the FASB or other authoritative standards groups with future effective dates are either not applicable or are not expected to be significant to the financial statements of the Company.

 

 F-7 

 

NOTE 3 - LOSS PER SHARE

 

Basic loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted loss per share gives effect to dilutive convertible securities, options, warrants and other potential common stock outstanding during the period; only in periods in which such effect is dilutive.

 

The following weighted average securities have been excluded from the calculation of net loss per share for the nine months ended June 30, 2017 and 2016, as the exercise price was greater than the average market price of the common shares: 

 

   2017  2016
(restated)
 Options    —      3,542,688 
 Warrants    722,500    722,500 

 

The following weighted average securities have been excluded from the calculation even though the exercise price was less than the market price of the common shares because the effect of including these potential shares was anti-dilutive due to the net loss incurred during the nine months ended June 30, 2017 and 2016:

 

  2017  2016
(restated)
Options  9,982,469    601,239 
Convertible Preferred Stock  8,850,000    8,850,000 

 

The effects of options and warrants on diluted earnings per share are reflected through the use of the treasury stock method and the excluded shares that are “in the money” are disclosed above in that manner.

 

NOTE 4 – DUE FROM RELATED PARTY

 

The Company expects to purchase “Closed Herd” collagen from Pure Med Farma, LLC (“PureMed”), a development stage company in which the Company’s Chief Executive Officer and Chief Financial Officer are member - owners. The Company and PureMed entered into a three year supply agreement on October 16, 2016 naming PureMed as the exclusive provider of collagen to the Company. The Company has agreed to assist PureMed by providing consultants to work on certain tasks in order to gain FDA approval. Such consultants’ costs will be reimbursed by PureMed. For the year ended September 30, 2016, the Company paid consultants on behalf of PureMed in the amount of $64,622 and was reflected at that time, with accrued interest at 8% as a non-current asset on the balance sheet. Accrued interest on these advances amounted to $2,646 at September 30, 2016.

 

On December 15, 2016, PureMed issued a note in the amount of $64,622 representing the advances for consultants through that date. Under the terms of the note, interest accrued at 8% per annum and was payable on or before December 15, 2017. The balance of the note plus accrued interest of $7,308 was repaid in full in May 2017.

 

In April 2017, the Company advanced $10,000 to its Chief Executive Officer. The loan does not bear interest and is due on demand.

 

 F-8 

 

NOTE 5 - LOANS PAYABLE

 

Loan Payable:

 

In February 2011, an investor advanced $10,000. The loan does not bear interest and is due on demand. At both June 30, 2017 and September 30, 2016, the loan payable totaled $10,000.

 

Loans Payable - Officer:

 

The Chief Executive Officer in fiscal year 2015 submitted for reimbursement Company expenses paid personally by him. At September 30, 2016, the balance owed to him was $13,009 and during the quarter ended December 31, 2016 that balance was repaid in full. The loan did not bear interest and was due on demand.

 

NOTE 6 - BRIDGE FINANCING

 

On December 21, 2011, the Company issued a $150,000 promissory note to an individual. The note bore interest so that the Company would repay $175,000 on the maturity date of June 21, 2012, which correlated to an effective rate of 31.23%. Additional interest of 10% was charged on any late payments. The note was not paid at the maturity date and the Company is incurring additional interest described above. At both June 30, 2017 and September 30, 2016, the note balance was $175,000. Interest expense was $13,089 and $13,137 for the nine months ended June 30, 2017 and 2016. Interest expense was $4,363 for both the three months ended June 30, 2017 and 2016, respectively.

 

Accrued interest on the note was $87,979 and $74,890 as of June 30, 2017 and September 30, 2016, respectively and is included in accrued expenses in the accompanying balance sheets.

 

NOTE 7 - INCOME TAXES

 

The Company did not incur current tax expense for the three and nine months ended June 30, 2017 and 2016.

 

At June 30, 2017, the Company had available approximately $4.4 million of net operating loss carry forwards which expire in the years 2029 through 2036. However, the use of the net operating loss carryforwards generated prior to September 30, 2011 totaling $0.7 million is limited under Section 382 of the Internal Revenue Code. Section 382 of the Internal Revenue Code of 1986, as amended (the Code), imposes an annual limitation on the amount of taxable income that may be offset by a corporation’s NOLs if the corporation experiences an “ownership change” as defined in Section 382 of the Code.

 

Significant components of the Company’s deferred tax assets at June 30, 2017 and September 30, 2016 are as follows:

 

  June 30, 2017  September 30, 2016
Net operating loss carry forwards $1,762,933   $1,630,872 
Unrealized loss  1,196,370    1,197,000 
Stock based compensation  40,104    40,104 
Accrued expenses  598,844    424,544 
Total deferred tax assets  3,598,251    3,292,520 
Valuation allowance  (3,598,251)   (3,292,520)
Net deferred tax assets $—     $—   

 

Due to the uncertainty of their realization, a valuation allowance has been established for all of the income tax benefit for these deferred tax assets.

 

At both June 30, 2017 and September 30, 2016, the Company had no material unrecognized tax benefits and no adjustments to liabilities or operations were required. The Company does not expect that its unrecognized tax benefits will materially increase within the next twelve months. The Company recognizes interest and penalties related to uncertain tax positions in general and administrative expense. As of June 30, 2017 and September 30, 2016 the Company has not recorded any provisions for accrued interest and penalties related to uncertain tax positions.

 

The Company files its federal income tax returns under a statute of limitations. The 2013 through 2016 tax years generally remain subject to examination by federal tax authorities.

 

 F-9 

 

NOTE 8 - STOCKHOLDERS’ DEFICIENCY

 

Preferred Stock: 

 

Series A

 

At both June 30, 2017 and September 30, 2016, 885,000 shares of Series A Preferred Stock (“Series A Preferred”) were outstanding.

 

Series A Preferred pays a dividend of 8% per annum on the stated value and have a liquidation preference equal to the stated value of the shares ($885,000 liquidation preference as of June 30, 2017 and September 30, 2016 plus dividends in arrears as per below). Each share of Series A Preferred Stock has an initial stated value of $1 and are convertible into shares of the Company’s common stock at the rate of 10 for 1.

 

The Series A Preferred Stock was marketed through a private placement memorandum that included a reference to a ratchet provision which would have allowed the holders of the stock to claim a better conversion rate based on other stock transactions conducted by the Company during the three year period following the original issuance of the shares.  Certain of the stock related transactions consummated by the Company during this time period may have triggered this ratchet provision, and thus created a claim by holders of the Series A Preferred Stock who purchased based on this representation for a greater conversion rate than initially provided.  The Company is currently negotiating with some of the remaining Series A holders regarding this claim and their conversion rate of their Series A Preferred Stock. Changes to the preferred stock conversion ratio may result in modification or extinguishment accounting. That may result in a deemed preferred stock dividend which would reduce net income available to common stockholders in the calculation of earnings per share. Certain of the smaller Series A holders have already converted or provided notice of conversion of their shares. In respect of this claim, the Company and its outside counsel determined that it is not possible to offer an opinion regarding the outcome.

 

The dividends are cumulative commencing on the issue date when and if declared by the Board of Directors. As of June 30, 2017 and September 30, 2016, dividends in arrears were $445,992 ($.48 per share) and $393,037 ($.44 per share), respectively. 

 

During the fourth quarter of 2016, the Company identified an error in the recording of accrued dividends on the Series A Convertible Preferred Stock. An immaterial error correction was made in the consolidated balance sheet at September 30, 2015, and in the consolidated statements of changes in stockholders’ deficiency as of October 1, 2014. Preferred stock dividends are no longer accrued and accordingly, a non-cash disclosure for preferred stock dividends in the amount of $53,149 on the statement of cash flows has been removed for the nine months ended June 30, 2016. 

 

Series B 

On January 23, 2012, the Company designated a new class of preferred stock called Series B Convertible Preferred Stock (“Series B Preferred”). Four million shares have been authorized with a liquidation preference of $2.00 per share. Each share of Series B Preferred is convertible into ten shares of common stock. Holders of Series B Convertible Preferred Stock have a right to a dividend (pro-rata to each holder) based on a percentage of the gross revenue earned by the Company in the United States, if any, and the number of outstanding shares of Series B Convertible Preferred Stock, as follows: Year 1 - Total Dividend to all Series B holders = .03 x Gross Revenue in the U.S. Year 2 - Total Dividend to all Series B holders = .02 x Gross Revenue in the U.S. Year 3 - Total Dividend to all Series B holders = .01 x Gross Revenue in the U.S. At June 30, 2017, no shares of Series B Preferred are outstanding. 

 

NOTE 9 - RELATED PARTY TRANSACTIONS

 

The Company’s principal executive office is located in Little Falls, New Jersey. The headquarters is located in the offices of McCoy Enterprises LLC, an entity controlled by Mr. McCoy. The office is attached to his residence but has its own entrances, restroom and kitchen facilities.

 

The Company also maintains an office at Carbon & Polymer Research Inc. ("CPR") in Pennington, New Jersey, which is the Company's materials and testing laboratory. An employee of the Company is an owner of CPR. On May 16, 2016, the Company entered into an agreement with CPR in which CPR will supply the collagen scaffolds used in the Company's production of the skin tissue. The contract contains a most favored customer clause guaranteeing the Company prices equal or lower than those charged to other customers. The Company has not yet made purchases from CPR.

 

No rent is charged for either premise.

 

 F-10 

 

NOTE 10 - STOCK-BASED COMPENSATION

 

The Company accounts for equity instruments issued in exchange for the receipt of goods or services from other than employees in accordance with FASB ASC 718, “Equity”. Costs are measured at the estimated fair value of the consideration received or the estimated fair value of the equity instruments issued, whichever is more reliably measurable. The value of equity instruments issued for consideration other than employee services is determined on the earlier of a performance commitment or completion of performance by the provider of goods or services as defined by ASC 718.

 

On January 6, 2011, the Company approved the issuance of 885,672 options to each of the four members of the board of directors at an exercise price of $0.035, as amended, per share that were to expire on December 22, 2015. Effective as of the expiration date, the Company extended the term of those options to December 31, 2018. All other contractual terms of the options remained the same. The option exercise price was compared to the fair market value of the Company’s shares on the date when the extension was authorized by the Company, resulting in the immediate recognition of $67,895 in compensation expense. There is no deferred compensation expense associated with this transaction, since all extended options had previously been fully vested. The extended options were valued utilizing the Black-Scholes option pricing model with the following assumptions: Exercise price of $0.035, expected volatility of 208%, risk free rate of 1.31% and expected term of 3.03 years. Stock based compensation amounted to $-0- and $67,895 for the nine months ended June 30, 2017 and 2016, respectively. Stock-based compensation is included in general and administrative expenses.

 

NOTE 11 - SUBSEQUENT EVENTS

 

Effective August 7, 2017, Dr. Craig Eagle resigned from of our board of directors. There was no known disagreement with Dr. Eagle on any matter relating to the Company’s operations, policies or practices.

 

 F-11 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

Forward-Looking Statements

 

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements generally are identified by the words “believes,” “project,” “expects,” “anticipates,” “estimates,” “intends,” “strategy,” “plan,” “may,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. We intend such forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of complying with those safe-harbor provisions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Further information concerning our business, including additional factors that could materially affect our financial results, is included herein and in our other filings with the SEC.

 

Overview

 

As previously reported, the Company continues to pursue its goal of obtaining FDA approval for its new product NovaDerm®. If approved, NovaDerm will be the first and only autologous, cultured skin substitute product allowed for medical use on burns requiring grafting.

 

NovaDerm® is a multi-layered tissue-engineered skin prepared by utilizing autologous (patient’s own) skin cells. It is anticipated to be a graftable collagen based cultured epithelium implant that produces a skin substitute containing both epidermal and dermal components with a collagen base. Clinically, we expect it to behave the same as split thickness allograft skin. It should therefore not be rejected by the immune system of the patient, unlike with porcine or cadaver cellular grafts. Immune system rejection is a serious concern in Xeno-transplant procedures which may have a cellular component. Additionally, the application of our cultured skin substitute should not require any specialized physician training because it is applied the same as in a standard allograft procedure.

 

Since the beginning of this year, our priority has been to raise additional funds to finalize our testing and IND application, and then begin clinical trials. We have received a request from the FDA for some additional testing which we believe can be done, at least in part, in-house. We have selected an outside university research facility to perform the exploratory testing and a commercial lab to do the standard type testing for the part of the required testing that must be performed independently, outside the Company's facilities. The portion of the testing that can be done in house is currently underway.

 

The drafting of the IND document is completed as far as we can given our existing funding and subject to update for the results of the additional testing.  As previously reported, a Clinical Research Organization has been selected and will assist in the preparation of the final IND submission. The estimated cost to perform the additional testing and complete the IND application to begin the clinical trials is still approximately $1.5 million. Once the IND is completed and approved by the FDA, we will be able to initiate the proposed clinical trials. Completion of the IND is expected to take 6 months after funding. We anticipate that, unlike most clinical trial, the NovaDerm trials should be completed in six to nine months. The reasons for this projected abbreviated time frame is: (a) the extensive documented history of the product technology; (b) the Independent product research conducted; (c) NovaDerm's Orphan Product Designation; (d) the estimated episode of care is only 1-3 months, depending on the degree of the burn; (e) NovaDerm's clinical surgical protocol is identical to those performed everyday with the current grafting procedures of harvesting healthy skin and grafting it onto a burned area or other artificial and skin substitutes; (f) the chance of immune rejection has essentially been eliminated or greatly reduced since NovaDerm is made from the patient's own cells; and (g) we expect that the length of the patient recruitment process will be more compressed than most trials due to the small number of subjects, 3-10 patients and the fact that the patient population is approximately 44,000 per year. In addition, the patient treatment will be confined to the 150 burn centers in the US. We continue to estimate that the cost of the clinical trials will be approximately $2 million. We also continue to be confident that the required funding will eventually be secured; however, no funding has been secured at this time. 

 

 4 

 

We have begun the preliminary planning for the clinical trials to the extent we are able based on funding constraints. We have chosen a CRO to assist in our IND submission and conducting the actual trials. Clinical site selection and patient recruitment should be somewhat simpler than other clinical trials, since, as noted, we are limited in site selection to the 150 burn centers qualified to treat catastrophic burns. In addition, the surgical protocol will be similar to the grafting procedures currently in use at those facilities.

 

The initial trials are planned to begin with ten subjects with an Initial Data Safety Monitoring Board (DSMB) review of safety on the first three subjects once they come in for their 6-month follow-up. We do not intend to interrupt our trial waiting for the DSMB report.

 

Our management is considering various possibilities and approaches to obtaining clinical trial materials and manufacturing. While no final decision has been made, management’s approach is to set up the trials so as to allow for a seamless transition into commercial production upon approval. 

 

In summary, as previously reported, we hope to accomplish the following milestones in 2017 and the first half of 2018:

 

  Secure interim financing to finalize product development, testing and needed to support the IND;

  Complete our additional testing and a second round of financing in order to conduct 10 patient clinical trials with NovaDerm® and finalize required manufacturing engineering runs and validations;

  Work with Pure Med Farma to finalize Collagen Scaffold Testing Specifications for NovaDerm®;

  Finalize contracts with the CRO and select the NovaDerm® clinical trial material manufacturer;

  Retain a Principal lead investigator, medical advisor, surgical trainer and dermopathologist;

  Select and execute contracts with two clinical study sites; and

  Perform a successful graft of NovaDerm® onto a clinical trial subject.

  

Results of Operations for the Three and Nine Months Ended June 30, 2017 and 2016

 

We generated no revenues from September 6, 2007 (date of inception) to June 30, 2017. We do not expect to generate revenues until we are able to obtain FDA approval of our product and thereafter successfully market and sell the product.

 

We incurred operating expenses of $194,966 and $785,572 for the three and nine months ended June 30, 2017, compared with operating expenses of $305,470 and $954,398 for the three and nine months ended June 30, 2016. General and administrative expenses accounted for substantially all of our operating expenses for the three and nine months ended June 30, 2017 (with $5,284 in R&D expenses during the nine-month period ended June 30, 2017). General and Administrative expenses accounted for all of our operating expenses for the three months ended June 30, 2016. In addition to administrative expense, stock based compensation of $67,895 and research and development expenses of $1,445 are included in the operating expenses for the nine months June 30, 2016.

 

Net other expense was $3,868 and $8,419 for the three and nine months ended June 30, 2017, as compared to net other expenses of $4,363 and $13,137 for the three and nine months ended June 30, 2016. Other income and expenses for the three and nine months ended June 30, 2017 consisted of only interest income and interest expenses. Other income and expenses for the same periods in 2016 consisted of only interest expense and no interest income which represented the main difference.

 

After provision for preferred stock dividends of $17,652 and $52,955 for the three and nine months ended June 30, 2017, we recorded a net loss available to common stockholders of $216,486 and $831,946 for the three and nine months ended June 30, 2017. By comparison, we recorded a net loss available to common stockholders of $327,485 and $1,020,684 for the three and nine months ended June 30, 2016.

 

 5 

 

Liquidity and Capital Resources

 

As of June 30, 2017, we had cash of $12,005 and total current assets of $57,066. As of June 30, 2017, we had current liabilities of $2,302,490. We therefore had negative working capital of $2,245,424.

 

Operating activities used $251,101 in cash for the nine months ended June 30, 2017. The decrease in cash was primarily attributable to funding the loss for the period offset by an increase in current liabilities.

 

Investing activities used $57,268 in cash during the reported period. Financing activities reflected cash outflow of $13,009 due to the repayment of related party loans. We note that the value of the shares of Amarantus we obtained and which created income from that sale of assets transaction have declined significantly in value since the consummation of the agreement.

 

We have issued various promissory notes to meet our short-term demands, the terms of which are provided in the notes to the consolidated financial statements accompanying this report. While this source of bridge financing has been helpful in the short term to meet our financial obligations, we will need additional financing to fund our operations, continue with the FDA approval process, and implement our business plan. Our short term financial needs to fund the clinical trials are estimated at $1.5- $3.5 million. Our long term financial needs are estimated at about $8-$10 million. 

 

Based upon our current financial condition, we do not have sufficient cash to operate our business at the current level for the next twelve months. We intend to fund operations through increased debt and/or equity financing arrangements, which may be insufficient to fund expenditures or other cash requirements. We plan to seek additional financing in a private equity offering to secure funding for operations. There can be no assurance that we will be successful in raising additional funding. If we are not able to secure additional funding, the implementation of our business plan will be impaired. There can be no assurance that such additional financing will be available to us on acceptable terms or at all.

 

Off Balance Sheet Arrangements

 

As of June 30, 2017, there were no off balance sheet arrangements.

 

Going Concern

 

Our consolidated financial statements have been prepared assuming that we will continue as a going concern which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. We have incurred operating losses from inception, expect to incur further losses in the development of our business, and have been dependent on funding operations through the issuance of convertible debt and private sale of equity securities. These conditions raise substantial doubt about our ability to continue as a going concern. Management’s plans include continuing to finance operations through the private or public placement of debt and/or equity securities and the reduction of expenditures. However, no assurance can be given at this time as to whether we will be able to achieve these objectives. The consolidated financial statements do not include any adjustment relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.

 

 6 

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

 

A smaller reporting company is not required to provide the information required by this Item.

 

Item 4. Controls and Procedures

 

Disclosure Controls and Procedures

 

We carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of June 30, 2017. This evaluation was carried out under the supervision and with the participation of our Chief Executive Officer and our Chief Financial Officer. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of June 30, 2017, our disclosure controls and procedures were not effective due to the presence of material weaknesses in internal control over financial reporting.

 

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company’s annual or interim financial statements will not be prevented or detected on a timely basis. Management has identified the following material weaknesses which have caused management to conclude that, as of June 30, 2017, our disclosure controls and procedures were not effective: (i) inadequate segregation of duties and effective risk assessment; and (ii) insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of both US GAAP and SEC guidelines.

 

Remediation Plan to Address the Material Weaknesses in Internal Control over Financial Reporting

 

Our company plans to take steps to enhance and improve the design of our internal controls over financial reporting. During the period covered by this quarterly report on Form 10-Q, we have not been able to remediate the material weaknesses identified above. To remediate such weaknesses, we plan to implement the following changes during our fiscal year ending September 30, 2017 (if funding is available): (i) appoint additional qualified personnel to address inadequate segregation of duties and ineffective risk management; and (ii) adopt sufficient written policies and procedures for accounting and financial reporting. The remediation efforts set out are largely dependent upon our securing additional financing to cover the costs of implementing the changes required. If we are unsuccessful in securing such funds, remediation efforts may be adversely affected in a material manner.

 

We are unable to remedy our controls related to the inadequate segregation of duties and ineffective risk management until we receive financing to hire additional employees. 

 

Changes in Internal Control over Financial Reporting

 

There were no changes in our internal control over financial reporting during the three months ended June 30, 2017 that have materially affected, or are reasonable likely to materially affect, our internal control over financial reporting.

 

 7 

 

PART II – OTHER INFORMATION

 

Item 1. Legal Proceedings 

 

We are not a party to any pending legal proceeding. We are not aware of any pending legal proceeding to which any of our officers, directors, or any beneficial holders of 5% or more of our voting securities are adverse to us or have a material interest adverse to us.

 

Item 1A. Risk Factors

 

A smaller reporting company is not required to provide the information required by this Item.

 

Item 2. Unregistered  Sales of Equity Securities and Use of Proceeds

 

The information set forth below relates to our issuances of securities without registration under the Securities Act of 1933 during the reporting period which were not previously included in a Quarterly Report on Form 10-Q or Current Report on Form 8-K.

 

For the three months ended June 30, 2017, we issued no shares of common stock. 

 

Item 3. Defaults upon Senior Securities

 

None

 

Item 4. Mine Safety Disclosures

 

Not applicable.

 

Item 5. Other Information

 

None

 

Item 6. Exhibits

 

Exhibit Number Description of Exhibit
31.1 Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2 Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1 Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 
101** The following materials from the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2017 formatted in Extensible Business Reporting Language (XBRL).
**Provided herewith  

 

 8 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  Regenicin, Inc.
   
Date: August 10, 2017
 

 

 

By: /s/ Randall McCoy
  Randall McCoy
Title: Chief Executive Officer and Director

 

 9 
 

EX-31.1 2 ex31_1.htm EX-31.1

CERTIFICATIONS

 

I, Randall McCoy, certify that;

 

1.   I have reviewed this quarterly report on Form 10-Q for the quarter ended June 30, 2017 of Regenicin, Inc (the “registrant”);

 

2.   Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.   Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.   The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a.   Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b.   Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c.   Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d.   Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.   The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a.   All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b.   Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 10, 2017

 

 

/s/ Randall McCoy

By: Randall McCoy

Title: Chief Executive Officer

EX-31.2 3 ex31_2.htm EX-31.2

CERTIFICATIONS

 

I, John J. Weber, certify that;

 

1.   I have reviewed this quarterly report on Form 10-Q for the quarter ended June 30, 2017 of Regenicin, Inc (the “registrant”);

 

2.   Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.   Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.   The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a.   Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b.   Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c.   Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d.   Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.   The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a.   All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b.   Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 10, 2017

 

 

/s/ John J. Weber

By: John J. Weber

Title: Chief Financial Officer

EX-32.1 4 ex32_1.htm EX-32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND

CHIEF FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the quarterly Report of Regenicin, Inc (the “Company”) on Form 10-Q for the quarter ended June 30, 2017 filed with the Securities and Exchange Commission (the “Report”), I, Randall McCoy, Chief Executive Officer of the Company, and, I John J. Weber, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

  1. The Report fully complies with the requirements of Section 13(a) and Section 15(d) of the Securities Exchange Act of 1934; and

 

  2. The information contained in the Report fairly presents, in all material respects, the consolidated financial condition of the Company as of the dates presented and the consolidated result of operations of the Company for the periods presented.

 

By: /s/ Randall McCoy
Name: Randall McCoy
Title: Principal Executive Officer and Director
Date: August 10, 2017


By: /s/ John J. Weber
Name: John J. Weber
Title: Principal Financial Officer and Director
Date: August 10, 2017


This certification has been furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

EX-101.INS 5 rgin-20170630.xml XBRL INSTANCE FILE 0001412659 2016-10-01 2017-06-30 0001412659 2017-08-01 0001412659 2016-09-30 0001412659 2017-06-30 0001412659 2015-10-01 2016-06-30 0001412659 us-gaap:SeriesAPreferredStockMember 2017-06-30 0001412659 us-gaap:SeriesAPreferredStockMember 2016-09-30 0001412659 us-gaap:SeriesBPreferredStockMember 2017-06-30 0001412659 RGIN:KnowHowSPAMember 2016-10-01 2017-06-30 0001412659 RGIN:ShareholderMember 2017-03-31 0001412659 RGIN:ShareholderrMember 2016-09-30 0001412659 us-gaap:ChiefExecutiveOfficerMember 2016-12-31 0001412659 us-gaap:ChiefExecutiveOfficerMember 2016-09-30 0001412659 RGIN:PromissoryNote2Member 2016-10-01 2017-06-30 0001412659 RGIN:PromissoryNote2Member 2017-06-30 0001412659 2016-06-30 0001412659 RGIN:ExclusionsFromCalculationsMember 2017-06-30 0001412659 RGIN:ExclusionsFromDilutedCalculationsMember 2016-06-30 0001412659 RGIN:FourBoardMemberOptionsMember 2016-10-01 2017-06-30 0001412659 RGIN:FourBoardMemberOptionsMember 2017-06-30 0001412659 2015-09-30 0001412659 RGIN:SaleAgreementMember 2016-10-01 2017-06-30 0001412659 us-gaap:SeriesAPreferredStockMember 2015-10-01 2016-06-30 0001412659 RGIN:FourBoardMemberOptionsMember 2015-10-01 2016-06-30 0001412659 RGIN:SupplyAgreementMember 2016-10-01 2017-06-30 0001412659 RGIN:SupplyAgreementMember 2016-09-30 0001412659 RGIN:PromissoryNote38Member 2016-10-01 2017-06-30 0001412659 RGIN:PromissoryNote38Member 2017-06-30 0001412659 RGIN:ExclusionsFromCalculations2Member 2017-06-30 0001412659 RGIN:ExclusionsFromDilutedCalculations2Member 2016-06-30 0001412659 RGIN:PromissoryNote2Member 2016-09-30 0001412659 2017-04-01 2017-06-30 0001412659 2016-04-01 2016-06-30 0001412659 RGIN:PromissoryNote39Member 2016-10-01 2017-06-30 0001412659 RGIN:PromissoryNote39Member 2017-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure 2017 10-Q 2017-06-30 false --09-30 Regenicin, Inc. 0001412659 No No Yes Smaller Reporting Company 157914 157914 5500000 5500000 885000 885000 885000 885000 157911410 157911410 885672 4400000 53149 4000000 200000000 200000000 780288 885058 194966 305470 67895 0 67895 785572 954398 194966 305470 -770572 -954398 -194966 -305470 -13089 -13137 -4363 -4363 -8419 -13137 -3868 -4363 -52955 -53149 -17652 -17652 40232 71807 22489 -21580 31330 51652 -251101 -595624 -13009 -57703 -206842 -717949 2010-07-21 2014-11-07 2016-10-16 3600000 218847 12005 66218 25986 262934 270423 175000 175000 10000 10000 10000 10000 13009 13009 1827841 2302490 885 885 10177515 10177515 -11799894 -12578885 -4428 -4428 0.001 0.001 0.001 0.001 4428360 4428360 1630872 1762933 0 Q3 7500 9075 778991 967535 198834 309833 15000 1575 -287250 -6400 -900 -777416 -1254785 -205234 -310733 2000000 3542688 9982469 601239 722500 722500 8850000 8850000 5284 1445 67268 445992 393037 10000 10000 0 2011-01-06 -831946 -1020684 -216486 -327485 2007-09-06 2011-12-21 2016-12-15 2017-04-30 2012-06-21 2017-12-15 150000 64622 10000 .3123 0.08 0.08 .10 175000 0 175000 -1468008 -2245424 359833 57066 1197000 1196370 292565 57066 359833 57066 230897 275316 87979 74890 1136001 1571751 435750 189000 40104 40104 424544 598844 3292520 3598251 3292520 3598251 2018-12-31 0.035 -785572 -954398 -194966 -305470 15000 -4670 -495 13089 13137 P3Y 64622 2029-01-01 67268 10000 1575 -0.01 -0.01 -0.00 -0.00 -0.01 -0.01 -0.00 -0.00 153483050 153483050 153483050 153483050 153483050 153483050 153483050 153483050 2646 7308 218847 12005 343428 1061377 57268 -64622 -13009 -73203 15500 10000 64622 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">Windstar, Inc. was incorporated in the state of Nevada on September 6, 2007. On July 19, 2010, the Company amended its Articles of Incorporation to change the name of the Company to Regenicin, Inc. (&#8220;Regenicin&#8221;). In September 2013, Regenicin formed a new wholly-owned subsidiary for the sole purpose of conducting research in the State of Georgia (together, the &#8220;Company&#8221;). The subsidiary has no activity since its formation due to the lack of funding. The Company&#8217;s original business was the development of a purification device. Such business was assigned to the Company&#8217;s former management in July 2010. The Company adopted a new business plan and intended to develop and commercialize a potentially lifesaving technology by the introduction of tissue-engineered skin substitutes to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds and a variety of plastic surgery procedures.</font></p> <p style="font: 10pt Gotham Book; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company entered into a Know-How License and Stock Purchase Agreement (the &#8220;Know-How SPA&#8221;) with Lonza Walkersville, Inc. (&#8220;Lonza Walkersville&#8221;) on July 21, 2010. Pursuant to the terms of the Know-How SPA, the Company paid Lonza Walkersville $3,000,000 and, in exchange, the Company was to receive an exclusive license to use certain proprietary know-how and information necessary to develop and seek approval by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) for the commercial sale of technology held by the Cutanogen Corporation (&#8220;Cutanogen&#8221;), a subsidiary of Lonza Walkersville. Additionally, pursuant to the terms of the Know-How SPA, the Company was entitled to receive certain related assistance and support from Lonza Walkersville upon payment of the $3,000,000. Under the Know-How SPA, once FDA approval was secured for the commercial sale of the technology, the Company would be entitled to acquire Cutanogen, Lonza Walkersville&#8217;s subsidiary, for $2,000,000 in cash. After prolonged attempts to negotiate disputes with Lonza Walkersville failed, on September 30, 2013, the Company filed a lawsuit against Lonza Walkersville, Lonza Group Ltd. and Lonza America, Inc. (&#8220;Lonza America&#8221;) in Fulton County Superior Court in the State of Georgia.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On November 7, 2014, the Company entered into an Asset Sale Agreement (the &#8220;Sale Agreement&#8221;) with Amarantus Bioscience Holdings, Inc., (&#8220;Amarantus&#8221;). Under the Sale Agreement, the Company agreed to sell to Amarantus all of its rights and claims in the litigation currently pending in the United States District Court for the District of New Jersey against Lonza Walkersville and Lonza America, Inc. (the &#8220;Lonza Litigation&#8221;). This includes all of the Cutanogen intellectual property rights and any Lonza manufacturing know-how technology. In addition, the Company agreed to sell the PermaDerm&#174; trademark and related intellectual property rights associated with it. The purchase price paid by Amarantus was: (i) $3,600,000 in cash, and (ii) shares of common stock in Amarantus having a value of $3,000,000 at the date of the transaction.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company used the net proceeds of the transaction to fund development of cultured cell technology and to pursue approval of the products through the FDA as well as for general and administrative expenses. The Company has been developing its own unique cultured skin substitute since the Company received Lonza&#8217;s termination notice.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Interim Financial Statements:</font></p> <p style="font: 10pt Gotham Book; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) for interim financial information and with Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and note disclosures required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the nine months ended June 30, 2017 are not necessarily indicative of the results that may be expected for the year ending September 30, 2017. These unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and footnotes thereto included in the Company's Annual Report on Form 10-K for the year ended September 30, 2016, as filed with the Securities and Exchange Commission.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Going Concern:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company's consolidated financial statements have been prepared assuming that the Company will continue as a going concern which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has incurred cumulative losses and has an accumulated deficit of approximately $12.6 million from inception, expects to incur further losses in the development of its business and has been dependent on funding operations through the issuance of convertible debt, private sale of equity securities, and the proceeds from the Sale Agreement. These conditions raise substantial doubt about the Company's ability to continue as a going concern. The Company is using the proceeds from the Sale Agreement to fund operations. Once the funds are exhausted, management plans to finance operations through the private or public placement of debt and/or equity securities. However, no assurance can be given at this time as to whether the Company will be able to obtain such financing. The consolidated financial statements do not include any adjustment relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</font></p> <p style="font: 10pt Gotham Book; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Financial Instruments and Fair Value Measurement:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company measures fair value of its financial assets on a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#8226; &#9;Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#8226; &#9;Level 2 - Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable or inputs that can be corroborated by observable market data for substantially the full term of the assets or liabilities.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#8226; &#9;Level 3 - Unobservable inputs which are supported by little or no market activity.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The carrying value of cash, prepaid expenses and other current assets, accounts payable, accrued expenses and all loans and notes payable in the Company&#8217;s consolidated balance sheets approximated their fair values as of June 30, 2017 and September 30, 2016 due to their short-term nature.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Common stock of Amarantus represents equity investments in common stock that the Company classifies as available for sale. Such investments are carried at fair value in the accompanying consolidated balance sheets. Fair value is determined under the guidelines of GAAP which defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. Realized gains and losses, determined using the first-in, first-out (FIFO) method, are included in net income (loss). Unrealized gains and losses considered to be temporary are reported as other comprehensive income (loss) and are included in stockholders equity. Other than temporary declines in the fair value of investment is included in other income (expense) on the statement of operations.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The common stock of Amarantus is valued at the closing price reported on the active market on which the security is traded. This valuation methodology is considered to be using Level 1 inputs. The total value of Amarantus common stock at June 30, 2017 is $9,075. The unrealized gain (loss) for the nine and three months ended June 30, 2017 was $1,575 and ($6,400), net of income taxes, respectively, and was reported as a component of comprehensive loss. The unrealized loss for the the nine and three months ended June 30, 2016 was ($287,250) and $(900), net of income taxes, respectively, and was also reported as a component of comprehensive loss. The Company has recognized other than temporary losses of $2,992,500 since the acquisition of the stock in connection with the Sale Agreement.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Reclassification:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Certain reclassifications have been made to the prior periods&#8217; statement of cash flows to conform to the current period&#8217;s presentation. The reclassifications did not affect the net income or retained earnings of the Company.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Recent Pronouncements:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In January 2016, the FASB issued ASU No. 2016-01, &#34;Financial Instruments-Overall: Recognition and Measurement of Financial Assets and Financial Liabilities&#34;. The new standard principally affects accounting standards for equity investments and financial liabilities where the fair value option has been elected, and the presentation and disclosure requirements for financial instruments. Upon the effective date of the new standards, all equity investments in unconsolidated entities, other than those accounted for using the equity method of accounting, will generally be measured at fair value through earnings. There will no longer be an available-for-sale classification and therefore, no changes in fair value will be reported in other comprehensive income (loss) for equity securities with readily determinable fair values. The new guidance on the classification and measurement will be effective for public business entities in fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The Company is currently evaluating the impact of ASU 2016-01 on its consolidated financial statements.&#160;</font></p> <p style="font: 10pt Gotham Book; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In February 2016, the FASB issued ASU 2016-02, Leases, (Topic 842). This new ASU represents a wholesale change to lease accounting and introduces a lease model that brings most leases on the balance sheet. It also eliminates the required use of bright-line tests in current U.S. GAAP for determining lease classification. This ASU is effective for annual periods beginning after December 15, 2018 (i.e., calendar periods beginning on January 1, 2019), and interim periods thereafter. Earlier application is permitted for all entities. The Company is currently evaluating the impact of ASU 2016-02 on its consolidated financial statements.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In March 2016, the FASB issued ASU No. 2016-09, Improvements to Employee Share-Based Payment Accounting, which is intended to simplify the accounting and reporting for employee share-based payment transactions. The pronouncement is effective for annual periods beginning after December 31, 2016, and with interim periods within those annual periods, with early adoption permitted. The adoption of this guidance is not expected to have a material impact on the Company's consolidated financial statements.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation, which is intended to reduce both (1) diversity in practice and (2) cost and complexity when applying the guidance in Topic 718, Compensation&#8212;Stock Compensation, to a change to the terms or conditions of a share-based payment award. The amendments in this Update are effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017 with early adoption permitted. The adoption of this guidance did not have a material impact on the Company's consolidated financial statements.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">All other recent pronouncements issued by the FASB or other authoritative standards groups with future effective dates are either not applicable or are not expected to be significant to the financial statements of the Company.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Basic loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted loss per share gives effect to dilutive convertible securities, options, warrants and other potential common stock outstanding during the period; only in periods in which such effect is dilutive.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The following weighted average securities have been excluded from the calculation of net loss per share for the nine months ended June 30, 2017 and 2016, as the exercise price was greater than the average market price of the common shares:&#160;</font></p> <p style="font: 10pt Gotham Book; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 40%; font: 10pt Gotham Book"> <tr style="vertical-align: bottom"> <td colspan="3" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="padding-bottom: 1pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">2017</font></td><td style="padding-bottom: 1pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">2016<br /> (restated)</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 51%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Options</font></td><td style="width: 1%; padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 20%; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;&#160;&#160;</font></td><td style="width: 1%; padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 2%; font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 20%; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,542,688</font></td><td style="width: 1%; padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Warrants</font></td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">722,500</font></td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">722,500</font></td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The following weighted average securities have been excluded from the calculation even though the exercise price was less than the market price of the common shares because the effect of including these potential shares was anti-dilutive due to the net loss incurred during the nine months ended June 30, 2017 and 2016:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 40%; font: 10pt Gotham Book"> <tr style="vertical-align: bottom"> <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2017</font></td><td style="padding-bottom: 1pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">2016<br /> (restated)</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="width: 54%; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">Options</font></td> <td style="width: 1%; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 20%; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">9,982,469</font></td><td style="width: 1%; padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 2%; font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 20%; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">601,239</font></td><td style="width: 1%; padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">Convertible Preferred Stock</font></td> <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">8,850,000</font></td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">8,850,000</font></td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The effects of options and warrants on diluted earnings per share are reflected through the use of the treasury stock method and the excluded shares that are &#8220;in the money&#8221; are disclosed above in that manner.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 40%; font: 10pt Gotham Book"> <tr style="vertical-align: bottom"> <td colspan="3" style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="padding-bottom: 1pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">2017</font></td><td style="padding-bottom: 1pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">2016<br /> (restated)</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 51%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Options</font></td><td style="width: 1%; padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 20%; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;&#160;&#160;</font></td><td style="width: 1%; padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 2%; font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 20%; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,542,688</font></td><td style="width: 1%; padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">Warrants</font></td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">722,500</font></td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">722,500</font></td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"></font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 40%; font: 10pt Gotham Book"> <tr style="vertical-align: bottom"> <td style="text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2017</font></td><td style="padding-bottom: 1pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">2016<br /> (restated)</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="width: 54%; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">Options</font></td> <td style="width: 1%; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 20%; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">9,982,469</font></td><td style="width: 1%; padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 2%; font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 20%; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">601,239</font></td><td style="width: 1%; padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">Convertible Preferred Stock</font></td> <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">8,850,000</font></td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">8,850,000</font></td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company expects to purchase &#8220;Closed Herd&#8221; collagen from Pure Med Farma, LLC (&#8220;PureMed&#8221;), a development stage company in which the Company&#8217;s Chief Executive Officer and Chief Financial Officer are member - owners. The Company and PureMed entered into a three year supply agreement on October 16, 2016 naming PureMed as the exclusive provider of collagen to the Company. The Company has agreed to assist PureMed by providing consultants to work on certain tasks in order to gain FDA approval. Such consultants&#8217; costs will be reimbursed by PureMed. For the year ended September 30, 2016, the Company paid consultants on behalf of PureMed in the amount of $64,622 and was reflected at that time, with accrued interest at 8%, as a non-current asset on the balance sheet. Accrued interest on these advances amounted to $2,646 at September 30, 2016.</font></p> <p style="font: 10pt Gotham Book; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On December 15, 2016, PureMed issued a note in the amount of $64,622 representing the advances for consultants through that date. Under the terms of the note, interest accrued at 8% per annum and was payable on or before December 15, 2017. The balance of the note plus accrued interest of $7,308 was repaid in full in May 2017.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In April 2017, the Company advanced $10,000 to its Chief Executive Officer. The loan does not bear interest and is due on demand.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Loan Payable:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In February 2011, an investor advanced $10,000. The loan does not bear interest and is due on demand. At both June 30, 2017 and September 30, 2016, the loan payable totaled $10,000.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Loans Payable - Officer:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Chief Executive Officer in fiscal year 2015 submitted for reimbursement Company expenses paid personally by him. At September 30, 2016, the balance owed to him was $13,009 and during the quarter ended December 31, 2016 that balance was repaid in full. The loan did not bear interest and was due on demand.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On December 21, 2011, the Company issued a $150,000 promissory note to an individual. The note bore interest so that the Company would repay $175,000 on the maturity date of June 21, 2012, which correlated to an effective rate of 31.23%. Additional interest of 10% was charged on any late payments. The note was not paid at the maturity date and the Company is incurring additional interest described above. At both June 30, 2017 and September 30, 2016, the note balance was $175,000. Interest expense was $13,089 and $13,137 for the nine months ended June 30, 2017 and 2016. Interest expense was $4,363 for both the three months ended June 30, 2017 and 2016, respectively.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Accrued interest on the note was $87,979 and $74,890 as of June 30, 2017 and September 30, 2016, respectively and is included in accrued expenses in the accompanying balance sheets.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company did not incur current tax expense for the three and nine months ended June 30, 2017 and 2016.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">At June 30, 2017, the Company had available approximately $4.4 million of net operating loss carry forwards which expire in the years 2029 through 2036. However, the use of the net operating loss carryforwards generated prior to September 30, 2011 totaling $0.7 million is limited under Section 382 of the Internal Revenue Code. Section 382 of the Internal Revenue Code of 1986, as amended (the Code), imposes an annual limitation on the amount of taxable income that may be offset by a corporation&#8217;s NOLs if the corporation experiences an &#8220;ownership change&#8221; as defined in Section 382 of the Code.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Significant components of the Company&#8217;s deferred tax assets at June 30, 2017 and September 30, 2016 are as follows:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 40%; font: 10pt Gotham Book"> <tr style="vertical-align: bottom"> <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="3" style="font-family: Times New Roman, Times, Serif; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">June 30, 2017</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="3" style="font-family: Times New Roman, Times, Serif; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">September 30, 2016</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="width: 54%; font-family: Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Net operating loss carry forwards</font></td> <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td><td style="width: 20%; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,762,933</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 2%; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td><td style="width: 20%; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,630,872</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Unrealized loss</font></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,196,370</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,197,000</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Stock based compensation</font></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">40,104</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">40,104</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">Accrued expenses</font></td> <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">598,844</font></td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">424,544</font></td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Total deferred tax assets</font></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,598,251</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,292,520</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">Valuation allowance</font></td> <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(3,598,251</font></td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(3,292,520</font></td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">Net deferred tax assets</font></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;&#160;&#160;</font></td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;&#160;&#160;</font></td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Due to the uncertainty of their realization, a valuation allowance has been established for all of the income tax benefit for these deferred tax assets.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">At both June 30, 2017 and September 30, 2016, the Company had no material unrecognized tax benefits and no adjustments to liabilities or operations were required. The Company does not expect that its unrecognized tax benefits will materially increase within the next twelve months. The Company recognizes interest and penalties related to uncertain tax positions in general and administrative expense. As of June 30, 2017 and September 30, 2016 the Company has not recorded any provisions for accrued interest and penalties related to uncertain tax positions.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company files its federal income tax returns under a statute of limitations. The 2013 through 2016 tax years generally remain subject to examination by federal tax authorities.</font></p> <p style="margin: 0pt"></p> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 40%; font: 10pt Gotham Book"> <tr style="vertical-align: bottom"> <td style="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="3" style="font-family: Times New Roman, Times, Serif; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">June 30, 2017</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td colspan="3" style="font-family: Times New Roman, Times, Serif; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">September 30, 2016</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="width: 54%; font-family: Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Net operating loss carry forwards</font></td> <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td><td style="width: 20%; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,762,933</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="width: 2%; font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td><td style="width: 20%; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,630,872</font></td><td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Unrealized loss</font></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,196,370</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">1,197,000</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Stock based compensation</font></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">40,104</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">40,104</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">Accrued expenses</font></td> <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">598,844</font></td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">424,544</font></td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Total deferred tax assets</font></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,598,251</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="font-family: Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">3,292,520</font></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">Valuation allowance</font></td> <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(3,598,251</font></td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">(3,292,520</font></td><td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,204)"> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">Net deferred tax assets</font></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;&#160;&#160;</font></td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;&#160;&#160;</font></td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td></tr> </table> <p style="margin: 0pt"></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Preferred Stock:&#160;</font></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Series A</font></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">At both June 30, 2017 and September 30, 2016, 885,000 shares of Series A Preferred Stock (&#8220;Series A Preferred&#8221;) were outstanding.</font></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Series A Preferred pays a dividend of 8% per annum on the stated value and have a liquidation preference equal to the stated value of the shares ($885,000 liquidation preference as of June 30, 2017 and September 30, 2016 plus dividends in arrears as per below). Each share of Series A Preferred Stock has an initial stated value of $1 and are convertible into shares of the Company&#8217;s common stock at the rate of 10 for 1.</font></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Series A Preferred Stock was marketed through a private placement memorandum that included a reference to a ratchet provision which would have allowed the holders of the stock to claim a better conversion rate based on other stock transactions conducted by the Company during the three year period following the original issuance of the shares. &#160;Certain of the stock related transactions consummated by the Company during this time period may have triggered this ratchet provision, and thus created a claim by holders of the Series A Preferred Stock who purchased based on this representation for a greater conversion rate than initially provided. &#160;The Company is currently negotiating with some of the remaining Series A holders regarding this claim and their conversion rate of their Series A Preferred Stock. Changes to the preferred stock conversion ratio may result in modification or extinguishment accounting. That may result in a deemed preferred stock dividend which would reduce net income available to common stockholders in the calculation of earnings per share. Certain of the smaller Series A holders have already converted or provided notice of conversion of their shares. In respect of this claim, the Company and its outside counsel determined that it is not possible to offer an opinion regarding the outcome.</font></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The dividends are cumulative commencing on the issue date when and if declared by the Board of Directors. As of June 30, 2017 and September 30, 2016, dividends in arrears were $445,992 ($.48 per share) and $393,037 ($.44 per share), respectively.&#160;</font></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">During the fourth quarter of 2016, the Company identified an error in the recording of accrued dividends on the Series A Convertible Preferred Stock. An immaterial error correction was made in the consolidated balance sheet at September 30, 2015, and in the consolidated statements of changes in stockholders&#8217; deficiency as of October 1, 2014. Preferred stock dividends are no longer accrued and accordingly, a non-cash disclosure for preferred stock dividends in the amount of $53,149 on the statement of cash flows has been removed for the nine months ended June 30, 2016.&#160;</font></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Series B&#160;</font></p> <p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On January 23, 2012, the Company designated a new class of preferred stock called Series B Convertible Preferred Stock (&#8220;Series B Preferred&#8221;). Four million shares have been authorized with a liquidation preference of $2.00 per share. Each share of Series B Preferred is convertible into ten shares of common stock. Holders of Series B Convertible Preferred Stock have a right to a dividend (pro-rata to each holder) based on a percentage of the gross revenue earned by the Company in the United States, if any, and the number of outstanding shares of Series B Convertible Preferred Stock, as follows: Year 1 - Total Dividend to all Series B holders = .03 x Gross Revenue in the U.S. Year 2 - Total Dividend to all Series B holders = .02 x Gross Revenue in the U.S. Year 3 - Total Dividend to all Series B holders = .01 x Gross Revenue in the U.S. At June 30, 2017, no shares of Series B Preferred are outstanding.&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company&#8217;s principal executive office is located in Little Falls, New Jersey. The headquarters is located in the offices of McCoy Enterprises LLC, an entity controlled by Mr. McCoy. The office is attached to his residence but has its own entrances, restroom and kitchen facilities.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company also maintains an office at Carbon &#38; Polymer Research Inc. (&#34;CPR&#34;) in Pennington, New Jersey, which is the Company's materials and testing laboratory. An employee of the Company is an owner of CPR. On May 16, 2016, the Company entered into an agreement with CPR in which CPR will supply the collagen scaffolds used in the Company's production of the skin tissue. The contract contains a most favored customer clause guaranteeing the Company prices equal or lower than those charged to other customers. The Company has not yet made purchases from CPR.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">No rent is charged for either premise.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company accounts for equity instruments issued in exchange for the receipt of goods or services from other than employees in accordance with FASB ASC 718, &#8220;Equity&#8221;. Costs are measured at the estimated fair value of the consideration received or the estimated fair value of the equity instruments issued, whichever is more reliably measurable. The value of equity instruments issued for consideration other than employee services is determined on the earlier of a performance commitment or completion of performance by the provider of goods or services as defined by ASC 718.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On January 6, 2011, the Company approved the issuance of 885,672 options to each of the four members of the board of directors at an exercise price of $0.035, as amended, per share that were to expire on December 22, 2015. Effective as of the expiration date, the Company extended the term of those options to December 31, 2018. All other contractual terms of the options remained the same. The option exercise price was compared to the fair market value of the Company&#8217;s shares on the date when the extension was authorized by the Company, resulting in the immediate recognition of $67,895 in compensation expense. There is no deferred compensation expense associated with this transaction, since all extended options had previously been fully vested. The extended options were valued utilizing the Black-Scholes option pricing model with the following assumptions: Exercise price of $0.035, expected volatility of 208%, risk free rate of 1.31% and expected term of 3.03 years. Stock based compensation amounted to $-0- and $67,895 for the nine months ended June 30, 2017 and 2016, respectively. Stock-based compensation is included in general and administrative expenses.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Effective August 7, 2017, Dr. Craig Eagle resigned from of our board of directors. There was no known disagreement with Dr. Eagle on any matter relating to the Company&#8217;s operations, policies or practices.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In January 2016, the FASB issued ASU No. 2016-01, &#34;Financial Instruments-Overall: Recognition and Measurement of Financial Assets and Financial Liabilities&#34;. The new standard principally affects accounting standards for equity investments and financial liabilities where the fair value option has been elected, and the presentation and disclosure requirements for financial instruments. Upon the effective date of the new standards, all equity investments in unconsolidated entities, other than those accounted for using the equity method of accounting, will generally be measured at fair value through earnings. There will no longer be an available-for-sale classification and therefore, no changes in fair value will be reported in other comprehensive income (loss) for equity securities with readily determinable fair values. The new guidance on the classification and measurement will be effective for public business entities in fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The Company is currently evaluating the impact of ASU 2016-01 on its consolidated financial statements.&#160;</font></p> <p style="font: 10pt Gotham Book; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In February 2016, the FASB issued ASU 2016-02, Leases, (Topic 842). This new ASU represents a wholesale change to lease accounting and introduces a lease model that brings most leases on the balance sheet. It also eliminates the required use of bright-line tests in current U.S. GAAP for determining lease classification. This ASU is effective for annual periods beginning after December 15, 2018 (i.e., calendar periods beginning on January 1, 2019), and interim periods thereafter. Earlier application is permitted for all entities. The Company is currently evaluating the impact of ASU 2016-02 on its consolidated financial statements.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In March 2016, the FASB issued ASU No. 2016-09, Improvements to Employee Share-Based Payment Accounting, which is intended to simplify the accounting and reporting for employee share-based payment transactions. The pronouncement is effective for annual periods beginning after December 31, 2016, and with interim periods within those annual periods, with early adoption permitted. The adoption of this guidance is not expected to have a material impact on the Company's consolidated financial statements.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation, which is intended to reduce both (1) diversity in practice and (2) cost and complexity when applying the guidance in Topic 718, Compensation&#8212;Stock Compensation, to a change to the terms or conditions of a share-based payment award. The amendments in this Update are effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017 with early adoption permitted. The adoption of this guidance did not have a material impact on the Company's consolidated financial statements.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">All other recent pronouncements issued by the FASB or other authoritative standards groups with future effective dates are either not applicable or are not expected to be significant to the financial statements of the Company.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Certain reclassifications have been made to the prior periods&#8217; statement of cash flows to conform to the current period&#8217;s presentation. The reclassifications did not affect the net income or retained earnings of the Company.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company measures fair value of its financial assets on a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#8226; &#9;Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#8226; &#9;Level 2 - Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable or inputs that can be corroborated by observable market data for substantially the full term of the assets or liabilities.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#8226; &#9;Level 3 - Unobservable inputs which are supported by little or no market activity.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The carrying value of cash, prepaid expenses and other current assets, accounts payable, accrued expenses and all loans and notes payable in the Company&#8217;s consolidated balance sheets approximated their fair values as of June 30, 2017 and September 30, 2016 due to their short-term nature.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Common stock of Amarantus represents equity investments in common stock that the Company classifies as available for sale. Such investments are carried at fair value in the accompanying consolidated balance sheets. Fair value is determined under the guidelines of GAAP which defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. Realized gains and losses, determined using the first-in, first-out (FIFO) method, are included in net income (loss). Unrealized gains and losses considered to be temporary are reported as other comprehensive income (loss) and are included in stockholders equity. Other than temporary declines in the fair value of investment is included in other income (expense) on the statement of operations.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The common stock of Amarantus is valued at the closing price reported on the active market on which the security is traded. This valuation methodology is considered to be using Level 1 inputs. The total value of Amarantus common stock at June 30, 2017 is $9,075. The unrealized gain (loss) for the nine and three months ended June 30, 2017 was $1,575 and ($6,400), net of income taxes, respectively, and was reported as a component of comprehensive loss. The unrealized loss for the the nine and three months ended June 30, 2016 was ($287,250) and $(900), net of income taxes, respectively, and was also reported as a component of comprehensive loss. The Company has recognized other than temporary losses of $2,992,500 since the acquisition of the stock in connection with the Sale Agreement.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company's consolidated financial statements have been prepared assuming that the Company will continue as a going concern which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has incurred cumulative losses and has an accumulated deficit of approximately $12.6 million from inception, expects to incur further losses in the development of its business and has been dependent on funding operations through the issuance of convertible debt, private sale of equity securities, and the proceeds from the Sale Agreement. These conditions raise substantial doubt about the Company's ability to continue as a going concern. The Company is using the proceeds from the Sale Agreement to fund operations. Once the funds are exhausted, management plans to finance operations through the private or public placement of debt and/or equity securities. However, no assurance can be given at this time as to whether the Company will be able to obtain such financing. The consolidated financial statements do not include any adjustment relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) for interim financial information and with Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and note disclosures required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the nine months ended June 30, 2017 are not necessarily indicative of the results that may be expected for the year ending September 30, 2017. These unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and footnotes thereto included in the Company's Annual Report on Form 10-K for the year ended September 30, 2016, as filed with the Securities and Exchange Commission.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> -2992500 153483050 EX-101.SCH 6 rgin-20170630.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - CONSOLIDATED BALANCE SHEET link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONSOLIDATED BALANCE SHEET (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - THE COMPANY link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - LOSS PER SHARE link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - DUE FROM RELATED PARTY link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - LOANS PAYABLE link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - BRIDGE FINANCING link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - STOCKHOLDERS DEFICIENCY link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - STOCK-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - BASIS OF PRESENTATION (Policies) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - LOSS PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - THE COMPANY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - BASIS OF PRESENTATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - LOSS PER SHARE - Schedule Of Income Loss per Common Share Exclusions (Details) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - DUE FROM RELATED PARTY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - LOANS PAYABLE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - BRIDGE FINANCING (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - INCOME TAXES - Deferred Tax Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - INCOME TAXES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - STOCKHOLDERS DEFICIENCY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 rgin-20170630_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 rgin-20170630_def.xml XBRL DEFINITION FILE EX-101.LAB 9 rgin-20170630_lab.xml XBRL LABEL FILE Equity Components [Axis] Series A Series B Finite Lived Intangible Assets By Major Class [Axis] Know How SPA Loan Payable [Axis] Shareholder Shareholder Chief Executive Officer Notes Payable [Axis] Promissory Note 2 Earning Per Share [Axis] Exclusions - Calcs Exclusions - Diluted Calcs 4 Board Members Sale of Assets [Axis] Sale Agreement Related Party [Axis] Supply Agmt Promissory Note 38 Exclusions - Calcs #2 Exclusions - Diluted Calcs #2 Promissory Note 39 Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Is Entity a Well-known Seasoned Issuer? Is Entity a Voluntary Filer? Is Entity's Reporting Status Current? Entity Filer Category Entity Public Float Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS CURRENT ASSETS Cash Prepaid expenses and other current assets Due from related party Common stock of Amarantus Corporation Total current assets Due from related party Total assets LIABILITIES AND STOCKHOLDERS DEFICIENCY CURRENT LIABILITIES Accounts payable Accrued expenses - other Accrued salaries - officers Bridge financing Loan payable Loans payable - officer Total current and total liabilities STOCKHOLDERS DEFICIENCY Series A 10% Convertible Preferred stock, $0.001 par value,5,500,000 shares authorized; 885,000 issued and outstanding Common stock, $0.001 par value; 200,000,000 shares authorized; 157,911,410 issued and 153,483,050 outstanding Additional paid-in capital Accumulated deficit Accumulated other comprehensive income Less: treasury stock; 4,428,360 shares at par Total stockholders deficiency Total liabilities and stockholders deficiency Series A Preferred Stock, Par Value Series A Preferred Stock, Shares Authorized Series A Preferred Stock, Issued and outstanding Common Stock, Par Value Common Stock, Shares Authorized Common Stock, Issued Treasury Stock, Issued Income Statement [Abstract] Revenues Operating expenses Research and development General and administrative Stock based compensation - general and administrative Total operating expenses Operating loss before other operating income Other operating income - reversal of accounts payable Loss from operations Other income (expenses) Interest expense Interest income Total other income (expenses) Net loss Preferred stock dividends Net loss available to common stockholders Loss per share Basic Loss per share Diluted Weighted average number of shares outstanding Basic Weighted average number of shares outstanding Diluted Consolidated Statements Of Comprehensive Income Loss Other comprehensive income (loss): Change in unrealized gain (loss) on available-for-sale securities, net of income taxes Comprehensive loss Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Net loss Adjustments to reconcile net income to net cash used in operating activities: Accrued interest on notes and loans payable Reversal of accounts payable Changes in operating assets and liabilities Prepaid expenses and other current assets Accounts payable Accrued expenses Accrued salaries - officers Net cash used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES Proceeds from repayment of loans from related party Advances to related parties Net cash provided by (used in) investing activities CASH FLOWS FROM FINANCING ACTIVITIES Proceeds of loans from officers Repayment of loans from officers Net cash used in financing activities NET DECREASE IN CASH CASH - BEGINNING OF PERIOD CASH - END OF PERIOD Supplemental disclosures of cash flow information: Cash paid for interest Cash paid for taxes Organization, Consolidation and Presentation of Financial Statements [Abstract] THE COMPANY BASIS OF PRESENTATION Notes to Financial Statements INCOME (LOSS) PER SHARE DUE FROM RELATED PARTY LOANS PAYABLE Receivables [Abstract] BRIDGE FINANCING Income Tax Disclosure [Abstract] INCOME TAXES Equity [Abstract] STOCKHOLDERS (DEFICIENCY) Related Party Transactions [Abstract] RELATED PARTY TRANSACTIONS Accounting Policies [Abstract] STOCK-BASED COMPENSATION Subsequent Events [Abstract] SUBSEQUENT EVENTS Interim Financial Statements Going Concern Financial Instruments and Fair Value Measurement Reclassification Recent Pronouncements Loss Per Share Tables Schedule Of Income Loss per Common Share Exclusions Schedule of Income Loss per Common Share Exclusions Deferred Tax Assets Statement [Table] Statement [Line Items] Finite-Lived Intangible Assets by Major Class [Axis] SaleOfAssetsAxis [Axis] Date of Incorporation Date of Agreement Payment to Acquire Intangible Assets Payment to Acquire Subsidiary Purchase Price Change in unrealized gains on available-for-sale securities, net of Loss on other than a temporary decline in fair value of investment EarningPerShareAxis [Axis] Options Convertible preferred stock NotesPayableAxis [Axis] Term of Agreement Advances to Consultant Date of Note Interest rate Debt Instrument, Principal Maturity Date Debt Instrument, Accrued Interest Debt Instrument, Balance LoanPayableAxis [Axis] Loans payable - related parties Repayments of loans from officers Loan payable, balance Debt Instrument Interest Rate Additional interest rate if late Accrued expenses other Deferred tax asset attributable to: Net operating loss carryover Unrealized loss Stock based compensation Accrued expenses Total deferred tax assets Valuation allowance Net deferred tax asset Operating Loss Carryforwards Carryforward Expiration Date Provision for income tax benefits Shareholders' Equity Class [Axis] Dividends Dividends payable Series B Preferred Stock, Shares Authorized Series B Preferred Stock, Outstanding Date of Issuance Common stock, Issued Common stock, Value Common Stock Option, Exercise Price Grant Date, Fair Value Date of Expiration ShareholderrMember Assets, Current Due from Related Parties, Noncurrent Assets Liabilities, Current Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest LiabilitiesAndStockholdersEquityAttributableToNoncontrollingInterestAbstract Operating Expenses Interest Income (Expense), Net Other Expenses Extraordinary Item, Gain (Loss), Net of Tax, Attributable to Noncontrolling Interest Gain (Loss) on Extinguishment of Debt Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Accounts Payable and Accrued Liabilities Increase (Decrease) in Accrued Salaries PaymentsForAdvanceToRelatedParty Net Cash Provided by (Used in) Investing Activities Net Cash Provided by (Used in) Financing Activities Cash [Default Label] DeferredTaxAssetsAccruedExpenses Deferred Tax Assets, Gross Deferred Tax Assets, Valuation Allowance Deferred Tax Assets, Net of Valuation Allowance EX-101.PRE 10 rgin-20170630_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.7.0.1
Document and Entity Information - shares
9 Months Ended
Jun. 30, 2017
Aug. 01, 2017
Document And Entity Information    
Entity Registrant Name Regenicin, Inc.  
Entity Central Index Key 0001412659  
Document Type 10-Q  
Document Period End Date Jun. 30, 2017  
Amendment Flag false  
Current Fiscal Year End Date --09-30  
Is Entity a Well-known Seasoned Issuer? No  
Is Entity a Voluntary Filer? No  
Is Entity's Reporting Status Current? Yes  
Entity Filer Category Smaller Reporting Company  
Entity Common Stock, Shares Outstanding   153,483,050
Document Fiscal Period Focus Q3  
Document Fiscal Year Focus 2017  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.7.0.1
CONSOLIDATED BALANCE SHEET - USD ($)
Jun. 30, 2017
Sep. 30, 2016
CURRENT ASSETS    
Cash $ 12,005 $ 218,847
Prepaid expenses and other current assets 25,986 66,218
Due from related party 10,000
Common stock of Amarantus Corporation 9,075 7,500
Total current assets 57,066 292,565
Due from related party 67,268
Total assets 57,066 359,833
CURRENT LIABILITIES    
Accounts payable 270,423 262,934
Accrued expenses - other 275,316 230,897
Accrued salaries - officers 1,571,751 1,136,001
Bridge financing 175,000 175,000
Loan payable 10,000 10,000
Loans payable - officer 13,009
Total current and total liabilities 2,302,490 1,827,841
STOCKHOLDERS DEFICIENCY    
Series A 10% Convertible Preferred stock, $0.001 par value,5,500,000 shares authorized; 885,000 issued and outstanding 885 885
Common stock, $0.001 par value; 200,000,000 shares authorized; 157,911,410 issued and 153,483,050 outstanding 157,914 157,914
Additional paid-in capital 10,177,515 10,177,515
Accumulated deficit (12,578,885) (11,799,894)
Accumulated other comprehensive income 1,575
Less: treasury stock; 4,428,360 shares at par (4,428) (4,428)
Total stockholders deficiency (2,245,424) (1,468,008)
Total liabilities and stockholders deficiency $ 57,066 $ 359,833
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.7.0.1
CONSOLIDATED BALANCE SHEET (Parenthetical) - $ / shares
Jun. 30, 2017
Sep. 30, 2016
Statement of Financial Position [Abstract]    
Series A Preferred Stock, Par Value $ 0.001 $ 0.001
Series A Preferred Stock, Shares Authorized 5,500,000 5,500,000
Series A Preferred Stock, Issued and outstanding 885,000 885,000
Common Stock, Par Value $ 0.001 $ 0.001
Common Stock, Shares Authorized 200,000,000 200,000,000
Common Stock, Issued 157,911,410 157,911,410
Treasury Stock, Issued 4,428,360 4,428,360
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.7.0.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
3 Months Ended 9 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Income Statement [Abstract]        
Revenues
Operating expenses        
Research and development 5,284 1,445
General and administrative 194,966 305,470 780,288 885,058
Stock based compensation - general and administrative 67,895
Total operating expenses 194,966 305,470 785,572 954,398
Operating loss before other operating income (194,966) (305,470) (785,572) (954,398)
Other operating income - reversal of accounts payable 15,000
Loss from operations (194,966) (305,470) (770,572) (954,398)
Other income (expenses)        
Interest expense (4,363) (4,363) (13,089) (13,137)
Interest income 495 4,670
Total other income (expenses) (3,868) (4,363) (8,419) (13,137)
Net loss (198,834) (309,833) (778,991) (967,535)
Preferred stock dividends (17,652) (17,652) (52,955) (53,149)
Net loss available to common stockholders $ (216,486) $ (327,485) $ (831,946) $ (1,020,684)
Loss per share Basic $ (0.00) $ (0.00) $ (0.01) $ (0.01)
Loss per share Diluted $ (0.00) $ (0.00) $ (0.01) $ (0.01)
Weighted average number of shares outstanding Basic 153,483,050 153,483,050 153,483,050 153,483,050
Weighted average number of shares outstanding Diluted 153,483,050 153,483,050 153,483,050 153,483,050
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.7.0.1
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($)
3 Months Ended 9 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Consolidated Statements Of Comprehensive Income Loss        
Net loss $ (198,834) $ (309,833) $ (778,991) $ (967,535)
Other comprehensive income (loss):        
Change in unrealized gain (loss) on available-for-sale securities, net of income taxes (6,400) (900) 1,575 (287,250)
Comprehensive loss $ (205,234) $ (310,733) $ (777,416) $ (1,254,785)
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.7.0.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
9 Months Ended
Jun. 30, 2017
Jun. 30, 2016
CASH FLOWS FROM OPERATING ACTIVITIES    
Net loss $ 778,991 $ 967,535
Adjustments to reconcile net income to net cash used in operating activities:    
Accrued interest on notes and loans payable 13,089 13,137
Stock based compensation - general and administrative 67,895
Reversal of accounts payable (15,000)
Changes in operating assets and liabilities    
Prepaid expenses and other current assets 40,232 71,807
Accounts payable 22,489 (21,580)
Accrued expenses 31,330 51,652
Accrued salaries - officers 435,750 189,000
Net cash used in operating activities (251,101) (595,624)
CASH FLOWS FROM INVESTING ACTIVITIES    
Proceeds from repayment of loans from related party 67,268
Advances to related parties (10,000) (64,622)
Net cash provided by (used in) investing activities 57,268 (64,622)
CASH FLOWS FROM FINANCING ACTIVITIES    
Proceeds of loans from officers 15,500
Repayment of loans from officers (13,009) (73,203)
Net cash used in financing activities (13,009) (57,703)
NET DECREASE IN CASH (206,842) (717,949)
CASH - BEGINNING OF PERIOD 218,847 1,061,377
CASH - END OF PERIOD 12,005 343,428
Supplemental disclosures of cash flow information:    
Cash paid for interest
Cash paid for taxes
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.7.0.1
THE COMPANY
9 Months Ended
Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
THE COMPANY

Windstar, Inc. was incorporated in the state of Nevada on September 6, 2007. On July 19, 2010, the Company amended its Articles of Incorporation to change the name of the Company to Regenicin, Inc. (“Regenicin”). In September 2013, Regenicin formed a new wholly-owned subsidiary for the sole purpose of conducting research in the State of Georgia (together, the “Company”). The subsidiary has no activity since its formation due to the lack of funding. The Company’s original business was the development of a purification device. Such business was assigned to the Company’s former management in July 2010. The Company adopted a new business plan and intended to develop and commercialize a potentially lifesaving technology by the introduction of tissue-engineered skin substitutes to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds and a variety of plastic surgery procedures.

 

The Company entered into a Know-How License and Stock Purchase Agreement (the “Know-How SPA”) with Lonza Walkersville, Inc. (“Lonza Walkersville”) on July 21, 2010. Pursuant to the terms of the Know-How SPA, the Company paid Lonza Walkersville $3,000,000 and, in exchange, the Company was to receive an exclusive license to use certain proprietary know-how and information necessary to develop and seek approval by the U.S. Food and Drug Administration (“FDA”) for the commercial sale of technology held by the Cutanogen Corporation (“Cutanogen”), a subsidiary of Lonza Walkersville. Additionally, pursuant to the terms of the Know-How SPA, the Company was entitled to receive certain related assistance and support from Lonza Walkersville upon payment of the $3,000,000. Under the Know-How SPA, once FDA approval was secured for the commercial sale of the technology, the Company would be entitled to acquire Cutanogen, Lonza Walkersville’s subsidiary, for $2,000,000 in cash. After prolonged attempts to negotiate disputes with Lonza Walkersville failed, on September 30, 2013, the Company filed a lawsuit against Lonza Walkersville, Lonza Group Ltd. and Lonza America, Inc. (“Lonza America”) in Fulton County Superior Court in the State of Georgia.

 

On November 7, 2014, the Company entered into an Asset Sale Agreement (the “Sale Agreement”) with Amarantus Bioscience Holdings, Inc., (“Amarantus”). Under the Sale Agreement, the Company agreed to sell to Amarantus all of its rights and claims in the litigation currently pending in the United States District Court for the District of New Jersey against Lonza Walkersville and Lonza America, Inc. (the “Lonza Litigation”). This includes all of the Cutanogen intellectual property rights and any Lonza manufacturing know-how technology. In addition, the Company agreed to sell the PermaDerm® trademark and related intellectual property rights associated with it. The purchase price paid by Amarantus was: (i) $3,600,000 in cash, and (ii) shares of common stock in Amarantus having a value of $3,000,000 at the date of the transaction.

 

The Company used the net proceeds of the transaction to fund development of cultured cell technology and to pursue approval of the products through the FDA as well as for general and administrative expenses. The Company has been developing its own unique cultured skin substitute since the Company received Lonza’s termination notice.

XML 18 R8.htm IDEA: XBRL DOCUMENT v3.7.0.1
BASIS OF PRESENTATION
9 Months Ended
Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
BASIS OF PRESENTATION

Interim Financial Statements:

 

The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and note disclosures required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the nine months ended June 30, 2017 are not necessarily indicative of the results that may be expected for the year ending September 30, 2017. These unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and footnotes thereto included in the Company's Annual Report on Form 10-K for the year ended September 30, 2016, as filed with the Securities and Exchange Commission.

 

Going Concern:

 

The Company's consolidated financial statements have been prepared assuming that the Company will continue as a going concern which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has incurred cumulative losses and has an accumulated deficit of approximately $12.6 million from inception, expects to incur further losses in the development of its business and has been dependent on funding operations through the issuance of convertible debt, private sale of equity securities, and the proceeds from the Sale Agreement. These conditions raise substantial doubt about the Company's ability to continue as a going concern. The Company is using the proceeds from the Sale Agreement to fund operations. Once the funds are exhausted, management plans to finance operations through the private or public placement of debt and/or equity securities. However, no assurance can be given at this time as to whether the Company will be able to obtain such financing. The consolidated financial statements do not include any adjustment relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

 

Financial Instruments and Fair Value Measurement:

 

The Company measures fair value of its financial assets on a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:

 

• Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.

 

• Level 2 - Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable or inputs that can be corroborated by observable market data for substantially the full term of the assets or liabilities.

 

• Level 3 - Unobservable inputs which are supported by little or no market activity.

 

The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.

 

The carrying value of cash, prepaid expenses and other current assets, accounts payable, accrued expenses and all loans and notes payable in the Company’s consolidated balance sheets approximated their fair values as of June 30, 2017 and September 30, 2016 due to their short-term nature.

 

Common stock of Amarantus represents equity investments in common stock that the Company classifies as available for sale. Such investments are carried at fair value in the accompanying consolidated balance sheets. Fair value is determined under the guidelines of GAAP which defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. Realized gains and losses, determined using the first-in, first-out (FIFO) method, are included in net income (loss). Unrealized gains and losses considered to be temporary are reported as other comprehensive income (loss) and are included in stockholders equity. Other than temporary declines in the fair value of investment is included in other income (expense) on the statement of operations.

 

The common stock of Amarantus is valued at the closing price reported on the active market on which the security is traded. This valuation methodology is considered to be using Level 1 inputs. The total value of Amarantus common stock at June 30, 2017 is $9,075. The unrealized gain (loss) for the nine and three months ended June 30, 2017 was $1,575 and ($6,400), net of income taxes, respectively, and was reported as a component of comprehensive loss. The unrealized loss for the the nine and three months ended June 30, 2016 was ($287,250) and $(900), net of income taxes, respectively, and was also reported as a component of comprehensive loss. The Company has recognized other than temporary losses of $2,992,500 since the acquisition of the stock in connection with the Sale Agreement.

 

Reclassification:

 

Certain reclassifications have been made to the prior periods’ statement of cash flows to conform to the current period’s presentation. The reclassifications did not affect the net income or retained earnings of the Company.

 

Recent Pronouncements:

 

In January 2016, the FASB issued ASU No. 2016-01, "Financial Instruments-Overall: Recognition and Measurement of Financial Assets and Financial Liabilities". The new standard principally affects accounting standards for equity investments and financial liabilities where the fair value option has been elected, and the presentation and disclosure requirements for financial instruments. Upon the effective date of the new standards, all equity investments in unconsolidated entities, other than those accounted for using the equity method of accounting, will generally be measured at fair value through earnings. There will no longer be an available-for-sale classification and therefore, no changes in fair value will be reported in other comprehensive income (loss) for equity securities with readily determinable fair values. The new guidance on the classification and measurement will be effective for public business entities in fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The Company is currently evaluating the impact of ASU 2016-01 on its consolidated financial statements. 

 

In February 2016, the FASB issued ASU 2016-02, Leases, (Topic 842). This new ASU represents a wholesale change to lease accounting and introduces a lease model that brings most leases on the balance sheet. It also eliminates the required use of bright-line tests in current U.S. GAAP for determining lease classification. This ASU is effective for annual periods beginning after December 15, 2018 (i.e., calendar periods beginning on January 1, 2019), and interim periods thereafter. Earlier application is permitted for all entities. The Company is currently evaluating the impact of ASU 2016-02 on its consolidated financial statements.

 

In March 2016, the FASB issued ASU No. 2016-09, Improvements to Employee Share-Based Payment Accounting, which is intended to simplify the accounting and reporting for employee share-based payment transactions. The pronouncement is effective for annual periods beginning after December 31, 2016, and with interim periods within those annual periods, with early adoption permitted. The adoption of this guidance is not expected to have a material impact on the Company's consolidated financial statements.

 

In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation, which is intended to reduce both (1) diversity in practice and (2) cost and complexity when applying the guidance in Topic 718, Compensation—Stock Compensation, to a change to the terms or conditions of a share-based payment award. The amendments in this Update are effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017 with early adoption permitted. The adoption of this guidance did not have a material impact on the Company's consolidated financial statements.

 

All other recent pronouncements issued by the FASB or other authoritative standards groups with future effective dates are either not applicable or are not expected to be significant to the financial statements of the Company.

XML 19 R9.htm IDEA: XBRL DOCUMENT v3.7.0.1
LOSS PER SHARE
9 Months Ended
Jun. 30, 2017
Notes to Financial Statements  
INCOME (LOSS) PER SHARE

Basic loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted loss per share gives effect to dilutive convertible securities, options, warrants and other potential common stock outstanding during the period; only in periods in which such effect is dilutive.

 

The following weighted average securities have been excluded from the calculation of net loss per share for the nine months ended June 30, 2017 and 2016, as the exercise price was greater than the average market price of the common shares: 

 

   2017  2016
(restated)
 Options    —      3,542,688 
 Warrants    722,500    722,500 

 

The following weighted average securities have been excluded from the calculation even though the exercise price was less than the market price of the common shares because the effect of including these potential shares was anti-dilutive due to the net loss incurred during the nine months ended June 30, 2017 and 2016:

 

  2017  2016
(restated)
Options  9,982,469    601,239 
Convertible Preferred Stock  8,850,000    8,850,000 

 

The effects of options and warrants on diluted earnings per share are reflected through the use of the treasury stock method and the excluded shares that are “in the money” are disclosed above in that manner.

XML 20 R10.htm IDEA: XBRL DOCUMENT v3.7.0.1
DUE FROM RELATED PARTY
9 Months Ended
Jun. 30, 2017
Notes to Financial Statements  
DUE FROM RELATED PARTY

The Company expects to purchase “Closed Herd” collagen from Pure Med Farma, LLC (“PureMed”), a development stage company in which the Company’s Chief Executive Officer and Chief Financial Officer are member - owners. The Company and PureMed entered into a three year supply agreement on October 16, 2016 naming PureMed as the exclusive provider of collagen to the Company. The Company has agreed to assist PureMed by providing consultants to work on certain tasks in order to gain FDA approval. Such consultants’ costs will be reimbursed by PureMed. For the year ended September 30, 2016, the Company paid consultants on behalf of PureMed in the amount of $64,622 and was reflected at that time, with accrued interest at 8%, as a non-current asset on the balance sheet. Accrued interest on these advances amounted to $2,646 at September 30, 2016.

 

On December 15, 2016, PureMed issued a note in the amount of $64,622 representing the advances for consultants through that date. Under the terms of the note, interest accrued at 8% per annum and was payable on or before December 15, 2017. The balance of the note plus accrued interest of $7,308 was repaid in full in May 2017.

 

In April 2017, the Company advanced $10,000 to its Chief Executive Officer. The loan does not bear interest and is due on demand.

XML 21 R11.htm IDEA: XBRL DOCUMENT v3.7.0.1
LOANS PAYABLE
9 Months Ended
Jun. 30, 2017
Notes to Financial Statements  
LOANS PAYABLE

Loan Payable:

 

In February 2011, an investor advanced $10,000. The loan does not bear interest and is due on demand. At both June 30, 2017 and September 30, 2016, the loan payable totaled $10,000.

 

Loans Payable - Officer:

 

The Chief Executive Officer in fiscal year 2015 submitted for reimbursement Company expenses paid personally by him. At September 30, 2016, the balance owed to him was $13,009 and during the quarter ended December 31, 2016 that balance was repaid in full. The loan did not bear interest and was due on demand.

XML 22 R12.htm IDEA: XBRL DOCUMENT v3.7.0.1
BRIDGE FINANCING
9 Months Ended
Jun. 30, 2017
Receivables [Abstract]  
BRIDGE FINANCING

On December 21, 2011, the Company issued a $150,000 promissory note to an individual. The note bore interest so that the Company would repay $175,000 on the maturity date of June 21, 2012, which correlated to an effective rate of 31.23%. Additional interest of 10% was charged on any late payments. The note was not paid at the maturity date and the Company is incurring additional interest described above. At both June 30, 2017 and September 30, 2016, the note balance was $175,000. Interest expense was $13,089 and $13,137 for the nine months ended June 30, 2017 and 2016. Interest expense was $4,363 for both the three months ended June 30, 2017 and 2016, respectively.

 

Accrued interest on the note was $87,979 and $74,890 as of June 30, 2017 and September 30, 2016, respectively and is included in accrued expenses in the accompanying balance sheets.

XML 23 R13.htm IDEA: XBRL DOCUMENT v3.7.0.1
INCOME TAXES
9 Months Ended
Jun. 30, 2017
Income Tax Disclosure [Abstract]  
INCOME TAXES

The Company did not incur current tax expense for the three and nine months ended June 30, 2017 and 2016.

 

At June 30, 2017, the Company had available approximately $4.4 million of net operating loss carry forwards which expire in the years 2029 through 2036. However, the use of the net operating loss carryforwards generated prior to September 30, 2011 totaling $0.7 million is limited under Section 382 of the Internal Revenue Code. Section 382 of the Internal Revenue Code of 1986, as amended (the Code), imposes an annual limitation on the amount of taxable income that may be offset by a corporation’s NOLs if the corporation experiences an “ownership change” as defined in Section 382 of the Code.

 

Significant components of the Company’s deferred tax assets at June 30, 2017 and September 30, 2016 are as follows:

 

  June 30, 2017  September 30, 2016
Net operating loss carry forwards $1,762,933   $1,630,872 
Unrealized loss  1,196,370    1,197,000 
Stock based compensation  40,104    40,104 
Accrued expenses  598,844    424,544 
Total deferred tax assets  3,598,251    3,292,520 
Valuation allowance  (3,598,251)   (3,292,520)
Net deferred tax assets $—     $—   

 

Due to the uncertainty of their realization, a valuation allowance has been established for all of the income tax benefit for these deferred tax assets.

 

At both June 30, 2017 and September 30, 2016, the Company had no material unrecognized tax benefits and no adjustments to liabilities or operations were required. The Company does not expect that its unrecognized tax benefits will materially increase within the next twelve months. The Company recognizes interest and penalties related to uncertain tax positions in general and administrative expense. As of June 30, 2017 and September 30, 2016 the Company has not recorded any provisions for accrued interest and penalties related to uncertain tax positions.

 

The Company files its federal income tax returns under a statute of limitations. The 2013 through 2016 tax years generally remain subject to examination by federal tax authorities.

XML 24 R14.htm IDEA: XBRL DOCUMENT v3.7.0.1
STOCKHOLDERS DEFICIENCY
9 Months Ended
Jun. 30, 2017
Equity [Abstract]  
STOCKHOLDERS (DEFICIENCY)

Preferred Stock: 

 

Series A

 

At both June 30, 2017 and September 30, 2016, 885,000 shares of Series A Preferred Stock (“Series A Preferred”) were outstanding.

 

Series A Preferred pays a dividend of 8% per annum on the stated value and have a liquidation preference equal to the stated value of the shares ($885,000 liquidation preference as of June 30, 2017 and September 30, 2016 plus dividends in arrears as per below). Each share of Series A Preferred Stock has an initial stated value of $1 and are convertible into shares of the Company’s common stock at the rate of 10 for 1.

 

The Series A Preferred Stock was marketed through a private placement memorandum that included a reference to a ratchet provision which would have allowed the holders of the stock to claim a better conversion rate based on other stock transactions conducted by the Company during the three year period following the original issuance of the shares.  Certain of the stock related transactions consummated by the Company during this time period may have triggered this ratchet provision, and thus created a claim by holders of the Series A Preferred Stock who purchased based on this representation for a greater conversion rate than initially provided.  The Company is currently negotiating with some of the remaining Series A holders regarding this claim and their conversion rate of their Series A Preferred Stock. Changes to the preferred stock conversion ratio may result in modification or extinguishment accounting. That may result in a deemed preferred stock dividend which would reduce net income available to common stockholders in the calculation of earnings per share. Certain of the smaller Series A holders have already converted or provided notice of conversion of their shares. In respect of this claim, the Company and its outside counsel determined that it is not possible to offer an opinion regarding the outcome.

 

The dividends are cumulative commencing on the issue date when and if declared by the Board of Directors. As of June 30, 2017 and September 30, 2016, dividends in arrears were $445,992 ($.48 per share) and $393,037 ($.44 per share), respectively. 

 

During the fourth quarter of 2016, the Company identified an error in the recording of accrued dividends on the Series A Convertible Preferred Stock. An immaterial error correction was made in the consolidated balance sheet at September 30, 2015, and in the consolidated statements of changes in stockholders’ deficiency as of October 1, 2014. Preferred stock dividends are no longer accrued and accordingly, a non-cash disclosure for preferred stock dividends in the amount of $53,149 on the statement of cash flows has been removed for the nine months ended June 30, 2016. 

 

Series B 

On January 23, 2012, the Company designated a new class of preferred stock called Series B Convertible Preferred Stock (“Series B Preferred”). Four million shares have been authorized with a liquidation preference of $2.00 per share. Each share of Series B Preferred is convertible into ten shares of common stock. Holders of Series B Convertible Preferred Stock have a right to a dividend (pro-rata to each holder) based on a percentage of the gross revenue earned by the Company in the United States, if any, and the number of outstanding shares of Series B Convertible Preferred Stock, as follows: Year 1 - Total Dividend to all Series B holders = .03 x Gross Revenue in the U.S. Year 2 - Total Dividend to all Series B holders = .02 x Gross Revenue in the U.S. Year 3 - Total Dividend to all Series B holders = .01 x Gross Revenue in the U.S. At June 30, 2017, no shares of Series B Preferred are outstanding. 

XML 25 R15.htm IDEA: XBRL DOCUMENT v3.7.0.1
RELATED PARTY TRANSACTIONS
9 Months Ended
Jun. 30, 2017
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS

The Company’s principal executive office is located in Little Falls, New Jersey. The headquarters is located in the offices of McCoy Enterprises LLC, an entity controlled by Mr. McCoy. The office is attached to his residence but has its own entrances, restroom and kitchen facilities.

 

The Company also maintains an office at Carbon & Polymer Research Inc. ("CPR") in Pennington, New Jersey, which is the Company's materials and testing laboratory. An employee of the Company is an owner of CPR. On May 16, 2016, the Company entered into an agreement with CPR in which CPR will supply the collagen scaffolds used in the Company's production of the skin tissue. The contract contains a most favored customer clause guaranteeing the Company prices equal or lower than those charged to other customers. The Company has not yet made purchases from CPR.

 

No rent is charged for either premise.

XML 26 R16.htm IDEA: XBRL DOCUMENT v3.7.0.1
STOCK-BASED COMPENSATION
9 Months Ended
Jun. 30, 2017
Accounting Policies [Abstract]  
STOCK-BASED COMPENSATION

The Company accounts for equity instruments issued in exchange for the receipt of goods or services from other than employees in accordance with FASB ASC 718, “Equity”. Costs are measured at the estimated fair value of the consideration received or the estimated fair value of the equity instruments issued, whichever is more reliably measurable. The value of equity instruments issued for consideration other than employee services is determined on the earlier of a performance commitment or completion of performance by the provider of goods or services as defined by ASC 718.

 

On January 6, 2011, the Company approved the issuance of 885,672 options to each of the four members of the board of directors at an exercise price of $0.035, as amended, per share that were to expire on December 22, 2015. Effective as of the expiration date, the Company extended the term of those options to December 31, 2018. All other contractual terms of the options remained the same. The option exercise price was compared to the fair market value of the Company’s shares on the date when the extension was authorized by the Company, resulting in the immediate recognition of $67,895 in compensation expense. There is no deferred compensation expense associated with this transaction, since all extended options had previously been fully vested. The extended options were valued utilizing the Black-Scholes option pricing model with the following assumptions: Exercise price of $0.035, expected volatility of 208%, risk free rate of 1.31% and expected term of 3.03 years. Stock based compensation amounted to $-0- and $67,895 for the nine months ended June 30, 2017 and 2016, respectively. Stock-based compensation is included in general and administrative expenses.

XML 27 R17.htm IDEA: XBRL DOCUMENT v3.7.0.1
SUBSEQUENT EVENTS
9 Months Ended
Jun. 30, 2017
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS

Effective August 7, 2017, Dr. Craig Eagle resigned from of our board of directors. There was no known disagreement with Dr. Eagle on any matter relating to the Company’s operations, policies or practices.

XML 28 R18.htm IDEA: XBRL DOCUMENT v3.7.0.1
BASIS OF PRESENTATION (Policies)
9 Months Ended
Jun. 30, 2017
Accounting Policies [Abstract]  
Interim Financial Statements

The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and note disclosures required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the nine months ended June 30, 2017 are not necessarily indicative of the results that may be expected for the year ending September 30, 2017. These unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and footnotes thereto included in the Company's Annual Report on Form 10-K for the year ended September 30, 2016, as filed with the Securities and Exchange Commission.

Going Concern

The Company's consolidated financial statements have been prepared assuming that the Company will continue as a going concern which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has incurred cumulative losses and has an accumulated deficit of approximately $12.6 million from inception, expects to incur further losses in the development of its business and has been dependent on funding operations through the issuance of convertible debt, private sale of equity securities, and the proceeds from the Sale Agreement. These conditions raise substantial doubt about the Company's ability to continue as a going concern. The Company is using the proceeds from the Sale Agreement to fund operations. Once the funds are exhausted, management plans to finance operations through the private or public placement of debt and/or equity securities. However, no assurance can be given at this time as to whether the Company will be able to obtain such financing. The consolidated financial statements do not include any adjustment relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Financial Instruments and Fair Value Measurement

The Company measures fair value of its financial assets on a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:

 

• Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.

 

• Level 2 - Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable or inputs that can be corroborated by observable market data for substantially the full term of the assets or liabilities.

 

• Level 3 - Unobservable inputs which are supported by little or no market activity.

 

The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.

 

The carrying value of cash, prepaid expenses and other current assets, accounts payable, accrued expenses and all loans and notes payable in the Company’s consolidated balance sheets approximated their fair values as of June 30, 2017 and September 30, 2016 due to their short-term nature.

 

Common stock of Amarantus represents equity investments in common stock that the Company classifies as available for sale. Such investments are carried at fair value in the accompanying consolidated balance sheets. Fair value is determined under the guidelines of GAAP which defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. Realized gains and losses, determined using the first-in, first-out (FIFO) method, are included in net income (loss). Unrealized gains and losses considered to be temporary are reported as other comprehensive income (loss) and are included in stockholders equity. Other than temporary declines in the fair value of investment is included in other income (expense) on the statement of operations.

 

The common stock of Amarantus is valued at the closing price reported on the active market on which the security is traded. This valuation methodology is considered to be using Level 1 inputs. The total value of Amarantus common stock at June 30, 2017 is $9,075. The unrealized gain (loss) for the nine and three months ended June 30, 2017 was $1,575 and ($6,400), net of income taxes, respectively, and was reported as a component of comprehensive loss. The unrealized loss for the the nine and three months ended June 30, 2016 was ($287,250) and $(900), net of income taxes, respectively, and was also reported as a component of comprehensive loss. The Company has recognized other than temporary losses of $2,992,500 since the acquisition of the stock in connection with the Sale Agreement.

Reclassification

Certain reclassifications have been made to the prior periods’ statement of cash flows to conform to the current period’s presentation. The reclassifications did not affect the net income or retained earnings of the Company.

Recent Pronouncements

In January 2016, the FASB issued ASU No. 2016-01, "Financial Instruments-Overall: Recognition and Measurement of Financial Assets and Financial Liabilities". The new standard principally affects accounting standards for equity investments and financial liabilities where the fair value option has been elected, and the presentation and disclosure requirements for financial instruments. Upon the effective date of the new standards, all equity investments in unconsolidated entities, other than those accounted for using the equity method of accounting, will generally be measured at fair value through earnings. There will no longer be an available-for-sale classification and therefore, no changes in fair value will be reported in other comprehensive income (loss) for equity securities with readily determinable fair values. The new guidance on the classification and measurement will be effective for public business entities in fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The Company is currently evaluating the impact of ASU 2016-01 on its consolidated financial statements. 

 

In February 2016, the FASB issued ASU 2016-02, Leases, (Topic 842). This new ASU represents a wholesale change to lease accounting and introduces a lease model that brings most leases on the balance sheet. It also eliminates the required use of bright-line tests in current U.S. GAAP for determining lease classification. This ASU is effective for annual periods beginning after December 15, 2018 (i.e., calendar periods beginning on January 1, 2019), and interim periods thereafter. Earlier application is permitted for all entities. The Company is currently evaluating the impact of ASU 2016-02 on its consolidated financial statements.

 

In March 2016, the FASB issued ASU No. 2016-09, Improvements to Employee Share-Based Payment Accounting, which is intended to simplify the accounting and reporting for employee share-based payment transactions. The pronouncement is effective for annual periods beginning after December 31, 2016, and with interim periods within those annual periods, with early adoption permitted. The adoption of this guidance is not expected to have a material impact on the Company's consolidated financial statements.

 

In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation, which is intended to reduce both (1) diversity in practice and (2) cost and complexity when applying the guidance in Topic 718, Compensation—Stock Compensation, to a change to the terms or conditions of a share-based payment award. The amendments in this Update are effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017 with early adoption permitted. The adoption of this guidance did not have a material impact on the Company's consolidated financial statements.

 

All other recent pronouncements issued by the FASB or other authoritative standards groups with future effective dates are either not applicable or are not expected to be significant to the financial statements of the Company.

XML 29 R19.htm IDEA: XBRL DOCUMENT v3.7.0.1
LOSS PER SHARE (Tables)
9 Months Ended
Jun. 30, 2017
Loss Per Share Tables  
Schedule Of Income Loss per Common Share Exclusions

   2017  2016
(restated)
 Options    —      3,542,688 
 Warrants    722,500    722,500 

Schedule of Income Loss per Common Share Exclusions

  2017  2016
(restated)
Options  9,982,469    601,239 
Convertible Preferred Stock  8,850,000    8,850,000 

 

XML 30 R20.htm IDEA: XBRL DOCUMENT v3.7.0.1
INCOME TAXES (Tables)
9 Months Ended
Jun. 30, 2017
Income Tax Disclosure [Abstract]  
Deferred Tax Assets

  June 30, 2017  September 30, 2016
Net operating loss carry forwards $1,762,933   $1,630,872 
Unrealized loss  1,196,370    1,197,000 
Stock based compensation  40,104    40,104 
Accrued expenses  598,844    424,544 
Total deferred tax assets  3,598,251    3,292,520 
Valuation allowance  (3,598,251)   (3,292,520)
Net deferred tax assets $—     $—   

XML 31 R21.htm IDEA: XBRL DOCUMENT v3.7.0.1
THE COMPANY (Details Narrative)
9 Months Ended
Jun. 30, 2017
USD ($)
Date of Incorporation Sep. 06, 2007
Sale Agreement  
Date of Agreement Nov. 07, 2014
Purchase Price $ 3,600,000
Know How SPA  
Date of Agreement Jul. 21, 2010
Payment to Acquire Subsidiary $ 2,000,000
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.7.0.1
BASIS OF PRESENTATION (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Sep. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]          
Common stock of Amarantus Corporation $ 9,075   $ 9,075   $ 7,500
Change in unrealized gains on available-for-sale securities, net of (6,400) $ (900) 1,575 $ (287,250)  
Accumulated deficit $ (12,578,885)   (12,578,885)   $ (11,799,894)
Loss on other than a temporary decline in fair value of investment     $ (2,992,500)    
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.7.0.1
LOSS PER SHARE - Schedule Of Income Loss per Common Share Exclusions (Details) - shares
Jun. 30, 2017
Jun. 30, 2016
Exclusions - Calcs    
Options  
Convertible preferred stock 722,500  
Exclusions - Diluted Calcs    
Options   3,542,688
Convertible preferred stock   722,500
Exclusions - Calcs #2    
Options 9,982,469  
Convertible preferred stock 8,850,000  
Exclusions - Diluted Calcs #2    
Options   601,239
Convertible preferred stock   8,850,000
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.7.0.1
DUE FROM RELATED PARTY (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Sep. 30, 2016
Interest income $ 495 $ 4,670  
Promissory Note 38          
Date of Note     Dec. 15, 2016    
Interest rate 8.00%   8.00%    
Debt Instrument, Principal $ 64,622   $ 64,622    
Maturity Date     Dec. 15, 2017    
Debt Instrument, Accrued Interest     $ 7,308    
Debt Instrument, Balance 0   $ 0    
Promissory Note 39          
Date of Note     Apr. 30, 2017    
Debt Instrument, Principal $ 10,000   $ 10,000    
Supply Agmt          
Date of Agreement     Oct. 16, 2016    
Term of Agreement     3 years    
Advances to Consultant         $ 64,622
Interest rate         8.00%
Debt Instrument, Accrued Interest     $ 2,646    
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.7.0.1
LOANS PAYABLE (Details Narrative) - USD ($)
9 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Mar. 31, 2017
Dec. 31, 2016
Sep. 30, 2016
Loan payable $ 10,000       $ 10,000
Loans payable - related parties       13,009
Repayments of loans from officers $ 67,268      
Shareholder          
Loan payable     $ 10,000    
Loan payable, balance     $ 10,000    
Shareholder          
Loan payable         10,000
Loan payable, balance         10,000
Chief Executive Officer          
Loans payable - related parties         $ 13,009
Loan payable, balance       $ 0  
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.7.0.1
BRIDGE FINANCING (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Sep. 30, 2016
Accrued expenses other $ 275,316   $ 275,316   $ 230,897
Interest expense (4,363) $ (4,363) $ (13,089) $ (13,137)  
Promissory Note 2          
Date of Note     Dec. 21, 2011    
Debt Instrument $ 150,000   $ 150,000    
Maturity Date     Jun. 21, 2012    
Interest Rate 31.23%   31.23%    
Additional interest rate if late 10.00%   10.00%    
Debt Instrument, Balance $ 175,000   $ 175,000   175,000
Accrued expenses other $ 87,979   $ 87,979   $ 74,890
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.7.0.1
INCOME TAXES - Deferred Tax Assets (Details) - USD ($)
Jun. 30, 2017
Sep. 30, 2016
Deferred tax asset attributable to:    
Net operating loss carryover $ 1,762,933 $ 1,630,872
Unrealized loss 1,196,370 1,197,000
Stock based compensation 40,104 40,104
Accrued expenses 598,844 424,544
Total deferred tax assets 3,598,251 3,292,520
Valuation allowance (3,598,251) (3,292,520)
Net deferred tax asset
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.7.0.1
INCOME TAXES (Details Narrative)
9 Months Ended
Jun. 30, 2017
USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Operating Loss Carryforwards $ 4,400,000
Carryforward Expiration Date Jan. 01, 2029
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.7.0.1
STOCKHOLDERS DEFICIENCY (Details Narrative) - USD ($)
9 Months Ended
Jun. 30, 2016
Jun. 30, 2017
Sep. 30, 2016
Series A Preferred Stock, Issued and outstanding   885,000 885,000
Series A      
Dividends $ 53,149    
Dividends payable   $ 445,992 $ 393,037
Series A Preferred Stock, Issued and outstanding   885,000 885,000
Series B      
Series B Preferred Stock, Shares Authorized   4,000,000  
Series B Preferred Stock, Outstanding   0  
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.7.0.1
STOCK-BASED COMPENSATION (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Sep. 30, 2016
Common stock, Issued 157,911,410   157,911,410   157,911,410
Common stock, Value $ 157,914   $ 157,914   $ 157,914
Stock based compensation - general and administrative $ 67,895  
4 Board Members          
Date of Issuance     Jan. 06, 2011    
Common stock, Issued 885,672   885,672    
Common Stock Option, Exercise Price $ 0.035   $ 0.035    
Stock based compensation - general and administrative     $ 0 $ 67,895  
Date of Expiration     Dec. 31, 2018    
EXCEL 41 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 42 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 43 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 45 FilingSummary.xml IDEA: XBRL DOCUMENT 3.7.0.1 html 35 131 1 false 16 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://RGIN/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - CONSOLIDATED BALANCE SHEET Sheet http://RGIN/role/ConsolidatedBalanceSheet CONSOLIDATED BALANCE SHEET Statements 2 false false R3.htm 00000003 - Statement - CONSOLIDATED BALANCE SHEET (Parenthetical) Sheet http://RGIN/role/ConsolidatedBalanceSheetParenthetical CONSOLIDATED BALANCE SHEET (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://RGIN/role/ConsolidatedStatementsOfOperations CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 00000005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) Sheet http://RGIN/role/ConsolidatedStatementsOfComprehensiveIncomeLoss CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) Statements 5 false false R6.htm 00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://RGIN/role/ConsolidatedStatementsOfCashFlows CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 00000007 - Disclosure - THE COMPANY Sheet http://RGIN/role/Company THE COMPANY Notes 7 false false R8.htm 00000008 - Disclosure - BASIS OF PRESENTATION Sheet http://RGIN/role/BasisOfPresentation BASIS OF PRESENTATION Notes 8 false false R9.htm 00000009 - Disclosure - LOSS PER SHARE Sheet http://RGIN/role/LossPerShare LOSS PER SHARE Notes 9 false false R10.htm 00000010 - Disclosure - DUE FROM RELATED PARTY Sheet http://RGIN/role/DueFromRelatedParty DUE FROM RELATED PARTY Notes 10 false false R11.htm 00000011 - Disclosure - LOANS PAYABLE Sheet http://RGIN/role/LoansPayable LOANS PAYABLE Notes 11 false false R12.htm 00000012 - Disclosure - BRIDGE FINANCING Sheet http://RGIN/role/BridgeFinancing BRIDGE FINANCING Notes 12 false false R13.htm 00000013 - Disclosure - INCOME TAXES Sheet http://RGIN/role/IncomeTaxes INCOME TAXES Notes 13 false false R14.htm 00000014 - Disclosure - STOCKHOLDERS DEFICIENCY Sheet http://RGIN/role/StockholdersDeficiency STOCKHOLDERS DEFICIENCY Notes 14 false false R15.htm 00000015 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://RGIN/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 15 false false R16.htm 00000016 - Disclosure - STOCK-BASED COMPENSATION Sheet http://RGIN/role/Stock-basedCompensation STOCK-BASED COMPENSATION Notes 16 false false R17.htm 00000017 - Disclosure - SUBSEQUENT EVENTS Sheet http://RGIN/role/SubsequentEvents SUBSEQUENT EVENTS Notes 17 false false R18.htm 00000018 - Disclosure - BASIS OF PRESENTATION (Policies) Sheet http://RGIN/role/BasisOfPresentationPolicies BASIS OF PRESENTATION (Policies) Policies 18 false false R19.htm 00000019 - Disclosure - LOSS PER SHARE (Tables) Sheet http://RGIN/role/LossPerShareTables LOSS PER SHARE (Tables) Tables http://RGIN/role/LossPerShare 19 false false R20.htm 00000020 - Disclosure - INCOME TAXES (Tables) Sheet http://RGIN/role/IncomeTaxesTables INCOME TAXES (Tables) Tables http://RGIN/role/IncomeTaxes 20 false false R21.htm 00000021 - Disclosure - THE COMPANY (Details Narrative) Sheet http://RGIN/role/CompanyDetailsNarrative THE COMPANY (Details Narrative) Details http://RGIN/role/Company 21 false false R22.htm 00000022 - Disclosure - BASIS OF PRESENTATION (Details Narrative) Sheet http://RGIN/role/BasisOfPresentationDetailsNarrative BASIS OF PRESENTATION (Details Narrative) Details http://RGIN/role/BasisOfPresentationPolicies 22 false false R23.htm 00000023 - Disclosure - LOSS PER SHARE - Schedule Of Income Loss per Common Share Exclusions (Details) Sheet http://RGIN/role/LossPerShare-ScheduleOfIncomeLossPerCommonShareExclusionsDetails LOSS PER SHARE - Schedule Of Income Loss per Common Share Exclusions (Details) Details 23 false false R24.htm 00000024 - Disclosure - DUE FROM RELATED PARTY (Details Narrative) Sheet http://RGIN/role/DueFromRelatedPartyDetailsNarrative DUE FROM RELATED PARTY (Details Narrative) Details http://RGIN/role/DueFromRelatedParty 24 false false R25.htm 00000025 - Disclosure - LOANS PAYABLE (Details Narrative) Sheet http://RGIN/role/LoansPayableDetailsNarrative LOANS PAYABLE (Details Narrative) Details http://RGIN/role/LoansPayable 25 false false R26.htm 00000026 - Disclosure - BRIDGE FINANCING (Details Narrative) Sheet http://RGIN/role/BridgeFinancingDetailsNarrative BRIDGE FINANCING (Details Narrative) Details http://RGIN/role/BridgeFinancing 26 false false R27.htm 00000027 - Disclosure - INCOME TAXES - Deferred Tax Assets (Details) Sheet http://RGIN/role/IncomeTaxes-DeferredTaxAssetsDetails INCOME TAXES - Deferred Tax Assets (Details) Details 27 false false R28.htm 00000028 - Disclosure - INCOME TAXES (Details Narrative) Sheet http://RGIN/role/IncomeTaxesDetailsNarrative INCOME TAXES (Details Narrative) Details http://RGIN/role/IncomeTaxesTables 28 false false R29.htm 00000029 - Disclosure - STOCKHOLDERS DEFICIENCY (Details Narrative) Sheet http://RGIN/role/StockholdersDeficiencyDetailsNarrative STOCKHOLDERS DEFICIENCY (Details Narrative) Details http://RGIN/role/StockholdersDeficiency 29 false false R30.htm 00000030 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative) Sheet http://RGIN/role/Stock-basedCompensationDetailsNarrative STOCK-BASED COMPENSATION (Details Narrative) Details http://RGIN/role/Stock-basedCompensation 30 false false All Reports Book All Reports rgin-20170630.xml rgin-20170630.xsd rgin-20170630_cal.xml rgin-20170630_def.xml rgin-20170630_lab.xml rgin-20170630_pre.xml true true ZIP 47 0001662252-17-000160-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001662252-17-000160-xbrl.zip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end